{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:04:12Z","timestamp":1792605852506,"version":"4.5.0"},"reference-count":301,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00948-6","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:54:54Z","timestamp":1781240094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The dual balance of the cytokine network: key messengers of immune activation and triggers of cytokine storm"],"prefix":"10.1186","volume":"14","author":[{"given":"Yixiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifang","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulong","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangzheqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"948_CR1","doi-asserted-by":"crossref","unstructured":"Commentary. Similarities of t cell function in cell-mediated immunity and antibody production. In: C S, B PE, Y T. Cell immunol. 1974;12(1):150\u201359. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0008874974900665.","DOI":"10.1016\/0008-8749(74)90066-5"},{"key":"948_CR2","doi-asserted-by":"publisher","unstructured":"Warren JL, Jian-Xin L. Strategies to therapeutically modulate cytokine action. Nat Rev Drug Discov. 2023;22(10):827\u2013854. https:\/\/doi.org\/10.1038\/s41573-023-00746-x.","DOI":"10.1038\/s41573-023-00746-x"},{"key":"948_CR3","doi-asserted-by":"publisher","unstructured":"Smriti KR, Emanual M, Siba PR. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13(4-5):490\u201349. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.008.","DOI":"10.1016\/j.autrev.2014.01.008"},{"key":"948_CR4","doi-asserted-by":"publisher","unstructured":"Robert AS, Caleb RG, G KC. Emerging principles of cytokine pharmacology and therapeutics. Nat Rev Drug Discov. 2022;22(1):21\u201337. https:\/\/doi.org\/10.1038\/s41573-022-00557-6.","DOI":"10.1038\/s41573-022-00557-6"},{"key":"948_CR5","doi-asserted-by":"publisher","unstructured":"Anniina V, Francesca Romana S, Jean Baptiste T, John J O, Olli S, Massimo G. JAK inhibitor selectivity: new opportunities, better drugs? Nat Rev Rheumatol. 2024;20(10):649\u2013665. https:\/\/doi.org\/10.1038\/s41584-024-01153-1.","DOI":"10.1038\/s41584-024-01153-1"},{"key":"948_CR6","doi-asserted-by":"publisher","unstructured":"Chao L, Dewei C, Kourosh K, Jacob G, Howard A Y, Guozhen L. Cytokines: from clinical significance to quantification. Adv Sci (Weinh). 2021;8(15):e2004433. https:\/\/doi.org\/10.1002\/advs.202004433.","DOI":"10.1002\/advs.202004433"},{"key":"948_CR7","doi-asserted-by":"publisher","unstructured":"Lisha L, Liu J, Lu J, Wu J, Zhang X, Ma T, et al. Interventions in cytokine signaling: novel horizons for psoriasis treatment. Front. Immunol. 2025;16:1573905. https:\/\/doi.org\/10.3389\/fimmu.2025.1573905.","DOI":"10.3389\/fimmu.2025.1573905"},{"key":"948_CR8","doi-asserted-by":"publisher","unstructured":"Rajendra K, Thirumala-Devi K. The \u2018cytokine storm\u2019: molecular mechanisms and therapeutic prospects. Trends Immunol. 2021;42(8):681\u2013705. https:\/\/doi.org\/10.1016\/j.it.2021.06.001.","DOI":"10.1016\/j.it.2021.06.001"},{"key":"948_CR9","doi-asserted-by":"publisher","unstructured":"Di L, Si-Yuan H, Jian-Hui S, Hua-Cai Z, Qing-Li C, Chu G, et al. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. Mil Med Res. 2022;9(1):56. https:\/\/doi.org\/10.1186\/s40779-022-00422-y.","DOI":"10.1186\/s40779-022-00422-y"},{"key":"948_CR10","doi-asserted-by":"publisher","unstructured":"David CF, Carl H J. Cytokine storm. N Engl J Med. 2020;383(23):2255-2273. https:\/\/doi.org\/10.1056\/NEJMra2026131.","DOI":"10.1056\/NEJMra2026131"},{"key":"948_CR11","doi-asserted-by":"publisher","unstructured":"Luka H, Tijana M, Mitja L, Jerneja F, Emil P, Irena M. The immunopathogenesis of a cytokine storm: the key mechanisms underlying severe COVID-19. Cytokine Growth Factor Rev. 2025;82:1\u201317. https:\/\/doi.org\/10.1016\/j.cytogfr.2024.12.003.","DOI":"10.1016\/j.cytogfr.2024.12.003"},{"key":"948_CR12","doi-asserted-by":"publisher","unstructured":"Kaori M, Mindy T, Hirohisa S, Stephen J G. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev. 2018;282(1):121\u201350. https:\/\/doi.org\/10.1111\/imr.12634.","DOI":"10.1111\/imr.12634"},{"issue":"11","key":"948_CR13","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.125.075290","volume":"153","author":"B Lin","year":"2026","unstructured":"Lin B, Wang J, Li C, Wang S, Shen M, Hu L, et al. CRLF1 secreted by cardiac fibroblasts promotes human hypertrophic cardiomyopathy. Circulation. 2026;153(11):845\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.075290.","journal-title":"Circulation"},{"key":"948_CR14","doi-asserted-by":"publisher","first-page":"1728730","DOI":"10.3389\/fimmu.2026.1728730","volume":"17","author":"R Li","year":"2026","unstructured":"Li R, Wei F, Yang M. TGF-\u03b2 in hematologic malignancies: molecular functions and clinical applications. Front. Immunol. 2026;17:1728730. https:\/\/doi.org\/10.3389\/fimmu.2026.1728730.","journal-title":"Front. Immunol"},{"issue":"5","key":"948_CR15","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1111\/ajt.16485","volume":"21","author":"CB Xie","year":"2021","unstructured":"Xie CB, Zhou J, Mackay S, Pober JS. Complement-activated human endothelial cells stimulate increased polyfunctionality in alloreactive t cells. Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surgeons. 2021;21(5):1902\u201309. https:\/\/doi.org\/10.1111\/ajt.16485.","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surgeons"},{"key":"948_CR16","doi-asserted-by":"publisher","unstructured":"Vennekens A, Laporte E, Hermans F, Cox B, Modave E, Janiszewski A, et al. Interleukin-6 is an activator of pituitary stem cells upon local damage, a competence quenched in the aging gland. Proc Natl Acad Sci USA. 2021;118(25):e2100052118. https:\/\/doi.org\/10.1073\/pnas.2100052118.","DOI":"10.1073\/pnas.2100052118"},{"key":"948_CR17","doi-asserted-by":"publisher","unstructured":"Soheil T, HamidReza M, Azin M, Kamran B, Sahar D, SeyedehBehnaz H, et al. Pathogenic and protective roles of cytokines in pemphigus: a systematic review. Cytokine 2020;129:155026. https:\/\/doi.org\/10.1016\/j.cyto.2020.155026.","DOI":"10.1016\/j.cyto.2020.155026"},{"key":"948_CR18","doi-asserted-by":"publisher","unstructured":"Silja S, Marek S, Fabian H, Philippe C B, Aaron O, Gisa T, et al. Hepatic ILC2 activity is regulated by liver inflammation-induced cytokines and effector CD4(+) t cells. Sci Rep. 2020;10(1):1071. https:\/\/doi.org\/10.1038\/s41598-020-57985-w.","DOI":"10.1038\/s41598-020-57985-w"},{"key":"948_CR19","doi-asserted-by":"publisher","unstructured":"Jovani C, Monica I V, Van Phi L, Sean-Paul N, Alborz K, Jenna M K, et al. Identification of IL-40, a novel b cell-associated cytokine. J Immunol. 2017;199(9):3326\u201335. https:\/\/doi.org\/10.4049\/jimmunol.1700534.","DOI":"10.4049\/jimmunol.1700534"},{"issue":"1","key":"948_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"IvashkivL B, Donlin LT. Regulation of type i interferon responses. Nat Rev Immunol. 2014;14(1):36\u201349. https:\/\/doi.org\/10.1038\/nri3581.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"948_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.immuni.2025.02.012","volume":"58","author":"AM Mujal","year":"2025","unstructured":"Mujal AM, Owyong M, Santosa EK, Sauter JC, Grassmann S, Pedde A, et al. Splenic TNF-\u03b1 signaling potentiates the innate-to-adaptive transition of antiviral NK cells. Immunity. 2025;58(3):585\u2013600. https:\/\/doi.org\/10.1016\/j.immuni.2025.02.012.","journal-title":"Immunity"},{"key":"948_CR22","doi-asserted-by":"publisher","first-page":"156525","DOI":"10.1016\/j.phymed.2025.156525","volume":"139","author":"G Liu","year":"2025","unstructured":"Liu G, Wang J, Liu J, Chen Y, Wang Z, Chu T, et al. Total glucosides of paeony alleviates Sjogren\u2019s syndrome by inhibiting Th1 and Th17 responses. Phytomed: Int J Phytotherapy Phytopharmacology. 2025;139:156525. https:\/\/doi.org\/10.1016\/j.phymed.2025.156525.","journal-title":"Phytomed: Int J Phytotherapy Phytopharmacology"},{"key":"948_CR23","doi-asserted-by":"publisher","unstructured":"Daniel C, Oana B, Ovidiu B, Ioana B. The dual role of tumor necrosis factor-alpha (TNF-\u03b1) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol (Dordr). 2020;43(1):1\u201318. https:\/\/doi.org\/10.1007\/s13402-019-00489-1.","DOI":"10.1007\/s13402-019-00489-1"},{"issue":"13","key":"948_CR24","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1158\/0008-5472.CAN-13-0002","volume":"73","author":"S Ardestani","year":"2013","unstructured":"Ardestani S, Li B, Deskins DL, Wu H, Massion PP, Young PP. Membrane versus soluble isoforms of TNF-\u03b1 exert opposing effects on tumor growth and survival of tumor-associated myeloid cells. Cancer Res. 2013;73(13):3938\u201350. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0002.","journal-title":"Cancer Res"},{"key":"948_CR25","doi-asserted-by":"publisher","unstructured":"Uysal H, Chavez-Galan L, Vesin D, Blaser G, Benkhoucha M, Ryffel B, et al. Transmembrane TNF and partially TNFR1 regulate TNFR2 expression and control inflammation in mycobacterial-induced pleurisy. IJMS. 2018;19(7):1959. https:\/\/doi.org\/10.3390\/ijms19071959.","DOI":"10.3390\/ijms19071959"},{"issue":"11","key":"948_CR26","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.3390\/ijms22115461","volume":"22","author":"A Ruiz","year":"2021","unstructured":"Ruiz A, Palacios Y, Garcia I, Chavez-Galan L. Transmembrane TNF and its receptors TNFR1 and TNFR2 in mycobacterial infections. IJMS. 2021;22(11):5461. https:\/\/doi.org\/10.3390\/ijms22115461.","journal-title":"IJMS"},{"issue":"5","key":"948_CR27","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1172\/JCI57748","volume":"121","author":"LA Dada","year":"2011","unstructured":"Dada LA, Sznajder JI. Mitochondrial Ca2+ and ROS take center stage to orchestrate TNF-\u03b1\u2013mediated inflammatory responses. J. Clin. Invest. 2011;121(5):1683\u201385. https:\/\/doi.org\/10.1172\/JCI57748.","journal-title":"J. Clin. Invest"},{"key":"948_CR28","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3389\/fimmu.2018.00784","volume":"9","author":"S Yang","year":"2018","unstructured":"Yang S, Wang J, Brand DD, Zheng SG. Role of TNF\u2013TNF receptor 2 signal in regulatory T cells and its therapeutic implications. Front. Immunol. 2018;9:784. https:\/\/doi.org\/10.3389\/fimmu.2018.00784.","journal-title":"Front. Immunol"},{"key":"948_CR29","doi-asserted-by":"publisher","unstructured":"Burkhard B, Sonia T, Melanie G. GM-CSF: from growth factor to central mediator of tissue inflammation. Immunity. 2016;45(5):963\u2013973. https:\/\/doi.org\/10.1016\/j.immuni.2016.10.026.","DOI":"10.1016\/j.immuni.2016.10.026"},{"key":"948_CR30","doi-asserted-by":"publisher","unstructured":"Hasan Onur D, Marc H, Andrea L, Jan-Oliver H, Bruno C, Oliver K. GM-CSF induces noninflammatory proliferation of microglia and disturbs electrical neuronal network rhythms in situ. J Neuroinflammation. 2020;17(1):235. https:\/\/doi.org\/10.1186\/s12974-020-01903-4.","DOI":"10.1186\/s12974-020-01903-4"},{"key":"948_CR31","doi-asserted-by":"publisher","unstructured":"Albert Z, Osamu Y. The chemokine superfamily revisited. Immunity. 2012;36(5):705\u201316. https:\/\/doi.org\/10.1016\/j.immuni.2012.05.008.","DOI":"10.1016\/j.immuni.2012.05.008"},{"key":"948_CR32","doi-asserted-by":"publisher","unstructured":"Seppe C, Mieke G, Paul P. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cell Mol Immunol. 2023;20(3):217\u201351. https:\/\/doi.org\/10.1038\/s41423-023-00974-6.","DOI":"10.1038\/s41423-023-00974-6"},{"key":"948_CR33","doi-asserted-by":"publisher","unstructured":"Yuxuan B, Chang T, Xiangyang X. CXCL3: a key player in tumor microenvironment and inflammatory diseases. Life Sci. 2024;348,12269. https:\/\/doi.org\/10.1016\/j.lfs.2024.122691.","DOI":"10.1016\/j.lfs.2024.122691"},{"key":"948_CR34","doi-asserted-by":"publisher","unstructured":"Olga S, Swantje IH, Leandros G, Reinhold MF. Chemokines and chemokine receptors in lymphoid tissue dynamics. Annu. Rev. Immunol. 2016;34:203\u201342. https:\/\/doi.org\/10.1146\/annurev-immunol-041015-055649.","DOI":"10.1146\/annurev-immunol-041015-055649"},{"key":"948_CR35","doi-asserted-by":"publisher","unstructured":"Andreas B, Clotilde B. The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironm ent. Am J Physiol Cell Physiol. 2020;318(3):C542\u201354. https:\/\/doi.org\/10.1152\/ajpcell.00378.2019.","DOI":"10.1152\/ajpcell.00378.2019"},{"issue":"11","key":"948_CR36","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.3390\/cancers13112560","volume":"13","author":"LG Guijarro","year":"2021","unstructured":"Guijarro LG, Sanmartin-Salinas P, P\u00e9rez-Cuevas E, Toledo-Lobo MV, Monserrat J, Zoullas S, et al. Possible role of IRS-4 in the origin of multifocal hepatocellular carcinoma. Cancers (Basel). 2021;13(11):2560. https:\/\/doi.org\/10.3390\/cancers13112560.","journal-title":"Cancers (Basel)"},{"key":"948_CR37","doi-asserted-by":"publisher","first-page":"111338","DOI":"10.1016\/j.mce.2021.111338","volume":"533","author":"C Bolitho","year":"2021","unstructured":"Bolitho C, Moscova M, Baxter RC, Marsh DJ. Amphiregulin increases migration and proliferation of epithelial ovarian cancer cells by inducing its own expression via PI3-kinase signaling. Mol Cellular Endocrinol. 2021;533:111338. https:\/\/doi.org\/10.1016\/j.mce.2021.111338.","journal-title":"Mol Cellular Endocrinol"},{"key":"948_CR38","doi-asserted-by":"publisher","unstructured":"Yuhong C, Cuixia D, Xuetian Z, Jing W, Fang W, Jun-Fang Y, et al. Transforming growth factor \u03b2 signaling pathway: a promising therapeutic target for cancer. J Cell Physiol. 2019;235(3):1903\u20131914. https:\/\/doi.org\/10.1002\/jcp.29108.","DOI":"10.1002\/jcp.29108"},{"key":"948_CR39","doi-asserted-by":"publisher","unstructured":"Alexander HS, Raouf A K. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009;78(6):539\u201352. https:\/\/doi.org\/10.1016\/j.bcp.2009.04.029.","DOI":"10.1016\/j.bcp.2009.04.029"},{"issue":"Pt 2","key":"948_CR40","doi-asserted-by":"publisher","first-page":"113339","DOI":"10.1016\/j.intimp.2024.113339","volume":"143","author":"W Fan","year":"2024","unstructured":"Fan W, Wang C, Xu K, Liang H, Chi Q. Ccl5 macrophages drive pro-inflammatory responses and neutrophil recruitment in sepsis-associated acute kidney injury. Int Immunopharmacol. 2024;143(Pt 2):113339. https:\/\/doi.org\/10.1016\/j.intimp.2024.113339.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"948_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s13105-018-0626-0","volume":"74","author":"Sofija Jovanovi\u0107 Stojanov","year":"2018","unstructured":"Jovanovi\u0107 Stojanov S, Martinovi\u0107 V, Jovanovi\u0107 Stojanov VV, Bogojevi\u0107 D, Poznanovi\u0107 G, Petrovi\u0107 A, Ivanovi\u0107-Mati\u0107 S, et al. Modulation of diabetes-related liver injury by the HMGB1\/TLR4 inflammatory pathway. J Physiol Biochem. 2018;74(2):345\u201358. https:\/\/doi.org\/10.1007\/s13105-018-0626-0.","journal-title":"J Physiol Biochem 2018"},{"key":"948_CR42","doi-asserted-by":"publisher","unstructured":"Maryam B, Seddigheh A, Shirin K, Laleh S, Hossein K. Aptamers against pro- and anti-inflammatory cytokines: a review. Inflammation. 2016;40(1):340\u201349. https:\/\/doi.org\/10.1007\/s10753-016-0477-1.","DOI":"10.1007\/s10753-016-0477-1"},{"key":"948_CR43","doi-asserted-by":"publisher","unstructured":"Kamal DM, Divaker C. Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res. 2011;31(10):695\u2013703. https:\/\/doi.org\/10.1089\/jir.2011.0065.","DOI":"10.1089\/jir.2011.0065"},{"key":"948_CR44","doi-asserted-by":"publisher","unstructured":"Sarah AH, Shakira JG, Tanya M W. Chimeric antigen receptor t-cell and bispecific antibody therapy in multiple myeloma: moving into the future. J Clin Oncol. 2023;41(27):4416\u20134429. https:\/\/doi.org\/10.1200\/JCO.23.00512.","DOI":"10.1200\/JCO.23.00512"},{"key":"948_CR45","doi-asserted-by":"publisher","unstructured":"OSM, D VA. Anti-inflammatory cytokines. Chest. 2000;117(4):1162\u201372. https:\/\/doi.org\/10.1378\/chest.117.4.1162.","DOI":"10.1378\/chest.117.4.1162"},{"key":"948_CR46","doi-asserted-by":"publisher","unstructured":"Sujin K, Toshio T, Masashi N, Tadamitsu K. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50(4):1007\u201323. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.026.","DOI":"10.1016\/j.immuni.2019.03.026"},{"key":"948_CR47","doi-asserted-by":"publisher","unstructured":"Juhyun S, Dae Won P, Sungwoo M, Han-Jin C, Jong Hak P, Hyeri S, et al. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the sepsis-3 definitions. BMC Infect Dis. 2019;19(1):968. https:\/\/doi.org\/10.1186\/s12879-019-4618-7.","DOI":"10.1186\/s12879-019-4618-7"},{"key":"948_CR48","doi-asserted-by":"publisher","unstructured":"Jingjing Z, Ye Z, Jun-Yu W, Bing W, Yu-Geng L. Expression pattern of serum interleukin-7 in elderly septic patients and its prognostic value for predicting short-term mortality. Cytokine. 2024;180:156664. https:\/\/doi.org\/10.1016\/j.cyto.2024.156664.","DOI":"10.1016\/j.cyto.2024.156664"},{"key":"948_CR49","doi-asserted-by":"publisher","unstructured":"Kraft R, Herndon DN, Finnerty CC, Cox RA, Song J, Jeschke MG. Predictive value of IL-8 for sepsis and severe infections after burn injury: a clinical study. Shock. 2015;43(3):222\u20137. https:\/\/doi.org\/10.1097\/SHK.0000000000000294.","DOI":"10.1097\/SHK.0000000000000294"},{"key":"948_CR50","doi-asserted-by":"publisher","unstructured":"Yin J, Chen Y, Huang JL, et al. Prognosis-related classification and dynamic monitoring of immune status in patients with sepsis: a prospective observational study. World J Emerg Med. 2021;12(3):185\u20131 https:\/\/doi.org\/10.5847\/wjem.j.1920-8642.2021.03.004.","DOI":"10.5847\/wjem.j.1920-8642.2021.03.004"},{"key":"948_CR51","doi-asserted-by":"publisher","unstructured":"Kamran G, Anna B, Charlotta E, Robert S. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021; 397(10275):754-766. https:\/\/doi.org\/10.1016\/s0140-6736(21)00184-7.","DOI":"10.1016\/s0140-6736(21)00184-7"},{"key":"948_CR52","doi-asserted-by":"publisher","unstructured":"Yang Z, Tiffany H, Xinjian C, Tasha T, James B, Aarushi B, et al. Interleukin 15 in cell-based cancer immunotherapy. Int J Mol Sci. 2022;23(13):7311. https:\/\/doi.org\/10.3390\/ijms23137311.","DOI":"10.3390\/ijms23137311"},{"key":"948_CR53","doi-asserted-by":"publisher","unstructured":"Sarah LG, Renu J, Abhishek V G, Daniel J C. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585\u2013600. https:\/\/doi.org\/10.1038\/nri3707.","DOI":"10.1038\/nri3707"},{"key":"948_CR54","doi-asserted-by":"publisher","unstructured":"Netea MG, Kullberg BJ, Verschueren I, Van der Meer JWM. Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1\u03b2. Eur J Immunol. 2000;30(10):3057\u201360. https:\/\/doi.org\/10.1002\/1521-4141(200010)30:10%3C3057::AID-IMMU3057%3E3.0.CO;2-P.","DOI":"10.1002\/1521-4141(200010)30:10%3C3057::AID-IMMU3057%3E3.0.CO;2-P"},{"key":"948_CR55","doi-asserted-by":"publisher","unstructured":"Anna H, Mykola T, Christian V, Thomas D, Timo B, Anne K, et al. Diagnostic utility of IL-18 plasma levels in distinguishing a bdominal from non-abdominal sepsis. Front Immunol. 2025;16(Unknown):1591262. https:\/\/doi.org\/10.3389\/fimmu.2025.1591262.","DOI":"10.3389\/fimmu.2025.1591262"},{"key":"948_CR56","doi-asserted-by":"publisher","unstructured":"Alexandros T, Stefanos M, Theodora P, Soultana M, Nikolaos K, Antonia S. The role of IL-19, IL-24, IL-21 and IL-33 in intestinal mucosa of inflammatory bowel disease: a narrative review. Arab J Gastroenterol. 2024;26(1):9\u201317. https:\/\/doi.org\/10.1016\/j.ajg.2024.01.002.","DOI":"10.1016\/j.ajg.2024.01.002"},{"key":"948_CR57","doi-asserted-by":"publisher","unstructured":"Kristen DP, Joseph TD, Stephen G, Irina V B. Cytokine modification of adoptive chimeric antigen receptor immunotherapyfor glioblastoma. Cancers (Basel). 2023;15(24):5852. https:\/\/doi.org\/10.3390\/cancers15245852.","DOI":"10.3390\/cancers15245852"},{"issue":"2","key":"948_CR58","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3760\/cma.j.issn.2095-4352.2015.02.012","volume":"27","author":"D Chang","year":"2015","unstructured":"Chang D, Jia J, Zang B. [Changes in plasma interleukin-33 concentration in sepsis and its correlation with seriousness of sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27(2):138\u201342. https:\/\/doi.org\/10.3760\/cma.j.issn.2095-4352.2015.02.012.","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"948_CR59","doi-asserted-by":"publisher","unstructured":"Zhu C, Aline B, Andreas R, Georg S. Anti -inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2018;15(1):9\u201317. https:\/\/doi.org\/10.1038\/s41584-018-0109-2.","DOI":"10.1038\/s41584-018-0109-2"},{"key":"948_CR60","doi-asserted-by":"publisher","unstructured":"Shuling Z, Yanwu L, Gang C, Xu W, Bin W. Sarcandra glabra (thunb.) Nakai alleviates DSS-induced ulcerative colitisby promoting restitution, restoring barrier function, and modulating IL-17\/notch1\/FoxP3 pathway in intestinal cells. J Ethnopharmacol. 2024;328:118131. https:\/\/doi.org\/10.1016\/j.jep.2024.118131.","DOI":"10.1016\/j.jep.2024.118131"},{"key":"948_CR61","doi-asserted-by":"publisher","unstructured":"Yong-Chun W, Guo-Peng W, Jian-Ping L, Lei L, Qing-Hong C. Elevated serum IL-37 concentrations in patients with sepsis. Med (Baltim). 2019;98(10):e14756. https:\/\/doi.org\/10.1097\/md.0000000000014756.","DOI":"10.1097\/md.0000000000014756"},{"key":"948_CR62","doi-asserted-by":"publisher","unstructured":"Evangelos JG, Massimo A, Frank B, Ioanna K, Christos P, Konstantina D, et al. Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality. EBioMedicine. 2024;109:105414. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105414.","DOI":"10.1016\/j.ebiom.2024.105414"},{"key":"948_CR63","doi-asserted-by":"publisher","unstructured":"Michihiro T, Ashwini P, Gabriella R, Denis C, Katherine J, Peter C, et al. A pairwise cytokine code explains the organism-wide response to sepsis. Nat Immunol. 2024;25(2):226\u201339. https:\/\/doi.org\/10.1038\/s41590-023-01722-8.","DOI":"10.1038\/s41590-023-01722-8"},{"key":"948_CR64","doi-asserted-by":"publisher","unstructured":"Hind H, S\u00e9bastien D, Fr\u00e9d\u00e9ric V, Abdulkader A, Yousra A, Hana E, et al. Multiple environmental signaling pathways control the differentiation of ROR\u03b3t-expressing regulatory t cells. Front Immunol. 2020;10:3007. https:\/\/doi.org\/10.3389\/fimmu.2019.03007.","DOI":"10.3389\/fimmu.2019.03007"},{"key":"948_CR65","doi-asserted-by":"publisher","unstructured":"Asuka T, Md Aminul I, Akm Humayun K, Kohtaro F, Michihiro T, Manami I, et al. Transcriptome modifications in the porcine intramuscular adipocytes during differentiation and exogenous stimulation with TNF-\u03b1 and serotonin. Int J Mol Sci. 2020;21(2):638. https:\/\/doi.org\/10.1021\/acs.jafc.7b02039.s001.","DOI":"10.1021\/acs.jafc.7b02039.s001"},{"key":"948_CR66","doi-asserted-by":"publisher","unstructured":"Seyede Sara S, Khashayar A, Saba B, Fatemeh R, Saeideh M, Nima R, et al. Current status of m1 and m2 macrophages pathway as drug targets for inflammatory bowel disease. Arch Immunol Ther Exp (Warsz). 2020;68(2):10. https:\/\/doi.org\/10.1007\/s00005-020-00576-4.","DOI":"10.1007\/s00005-020-00576-4"},{"key":"948_CR67","doi-asserted-by":"publisher","unstructured":"Harbour SN, DiToro DF, Witte SJ, Zindl CL, Gao M, Schoeb TR, et al. TH17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity. Sci Immunol. 2020;5(49):eaaw2262. https:\/\/doi.org\/10.1126\/sciimmunol.aaw2262.","DOI":"10.1126\/sciimmunol.aaw2262"},{"issue":"8","key":"948_CR68","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1080\/08923973.2023.2215405","volume":"90","author":"SA Diehl","year":"2012","unstructured":"Reza E, Salar H, Amirhosein M, Amir S, Armin J, Abdolreza E. Targeting the cGAS-STING pathway as an inflammator y crossroad in coronavirus disease 2019. COVID-19). Immunopharmacol Immunotoxicol. 2023;45(6):639-649. https:\/\/doi.org\/10.1080\/08923973.2023.2215405.","journal-title":"Immunol Cell Biol"},{"key":"948_CR69","doi-asserted-by":"publisher","unstructured":"Joanna B, Namrata G, Xiang Z, Elijah W C, Monika M, Desmond WH, et al. T cell receptor and cytokine signal integration in CD8(+) t cells is mediated by the protein themis. Nat Immunol. 2020;21(2):186\u2013198. https:\/\/doi.org\/10.1038\/s41590-019-0570-3.","DOI":"10.1038\/s41590-019-0570-3"},{"key":"948_CR70","doi-asserted-by":"publisher","unstructured":"Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al. Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity. 2020;52(1). https:\/\/doi.org\/10.1016\/j.immuni.2019.12.005.","DOI":"10.1016\/j.immuni.2019.12.005"},{"key":"948_CR71","doi-asserted-by":"publisher","unstructured":"Weibin Y. Roles of cytokine storm in sepsis progression: biomarkers, and emerging therapeutic strategies. Front Immunol. 2025;16:1696366. https:\/\/doi.org\/10.3389\/fimmu.2025.1696366.","DOI":"10.3389\/fimmu.2025.1696366"},{"key":"948_CR72","doi-asserted-by":"publisher","unstructured":"Yupeng H, Liangcheng Q, Haixing W, Zhiwei S, Peng K, Xiaodan W. Focus on the cGAS-STING signaling pathway in sepsisand its inflammatory regulatory effects. J Inflamm Res. 2024;17:3629\u201339. https:\/\/doi.org\/10.2147\/jir.s465978.","DOI":"10.2147\/jir.s465978"},{"key":"948_CR73","doi-asserted-by":"publisher","unstructured":"Fei X, Yoshinori K, Hiroki O, Shingo Y, Zerong Y, J JA. Morphine induces inflammatory responses via both TLR4 and cGAS-STING signaling pathways. Cytokine. 2024;183:156737. https:\/\/doi.org\/10.1016\/j.cyto.2024.156737.","DOI":"10.1016\/j.cyto.2024.156737"},{"key":"948_CR74","doi-asserted-by":"publisher","unstructured":"Reza E, Salar H, Amirhosein M, Amir S, Armin J, Abdolreza E. Targeting the cGAS-STING pathway as an inflammatory crossroad in coronavirus disease 2019. COVID-19). Immunopharmacol Immunotoxicol 2023;45(6):639\u201349. https:\/\/doi.org\/10.1080\/08923973.2023.2215405.","DOI":"10.1080\/08923973.2023.2215405"},{"key":"948_CR75","doi-asserted-by":"publisher","unstructured":"Christine WW, Trine R, Henriette A, Jarle V, S\u00f8ren E, Arne Y, et al. TLR4 inhibition attenuated LPS-induced proinflammatory signaling and cytokine release in mouse hearts and cardiomyocytes. Immun Inflamm Dis. 2025;13(1):e70133. https:\/\/doi.org\/10.1002\/iid3.70133.","DOI":"10.1002\/iid3.70133"},{"key":"948_CR76","doi-asserted-by":"publisher","unstructured":"Ming M, Wei J, Rongbin Z. Damps and D AMP-sensing receptors in inflammation and diseases. Immunity. 2024;57(4):752\u201371. https:\/\/doi.org\/10.1016\/j.immuni.2024.03.002.","DOI":"10.1016\/j.immuni.2024.03.002"},{"key":"948_CR77","doi-asserted-by":"publisher","first-page":"116698","DOI":"10.1016\/j.biopha.2024.116698","volume":"175","author":"S Zhong","year":"2024","unstructured":"Zhong S, Zhou Q, Yang J, Zhang Z, Zhang X, Liu J, et al. Relationship between the cGAS\u2212STING and NF-\u03bab pathways-role in neurotoxicity. Biomed Pharmacother. 2024;175:116698. https:\/\/doi.org\/10.1016\/j.biopha.2024.116698.","journal-title":"Biomed Pharmacother"},{"key":"948_CR78","doi-asserted-by":"publisher","unstructured":"Min-Jun W, Hai-Ling Z, Fei C, Xiao-Jing G, Qing-Gui L, Jin H. The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases. Exp Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s40164-024-00527-1.","DOI":"10.1186\/s40164-024-00527-1"},{"key":"948_CR79","doi-asserted-by":"publisher","unstructured":"Chiara B, Francesca Romana M, Sara G, Peter L, Raffaele D. The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. Eur Heart J. 2021. https:\/\/doi.org\/10.1093\/eurheartj\/ehab447.","DOI":"10.1093\/eurheartj\/ehab447"},{"key":"948_CR80","doi-asserted-by":"publisher","unstructured":"Hongwei Q, Andrew T H, Yudong L, Stephanie L R, Lora L Y, Etty N B. SOCS3 deficiency promotes m1 macrophage polarization and inflammation. J Immunol. 2012. https:\/\/doi.org\/10.4049\/jimmunol.1201168.","DOI":"10.4049\/jimmunol.1201168"},{"key":"948_CR81","doi-asserted-by":"publisher","unstructured":"Peter H, Jean-Philippe P, Celine H, Geum-Youn G, Jorge Matias C, Xueru M, et al. The HMGB1\/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J. Clin. Invest. 2015. https:\/\/doi.org\/10.1172\/jci76887.","DOI":"10.1172\/jci76887"},{"key":"948_CR82","doi-asserted-by":"publisher","unstructured":"Lu Z, Yi-Fei Z, Fu-Hua Y, Han-Qing M, Zhi C, Lu Z. Mitochondrial DNA leakage induces odontoblast inflammation via the cGAS-STING pathway. Cell Commun Signal 2021. https:\/\/doi.org\/10.1186\/s12964-021-00738-7.","DOI":"10.1186\/s12964-021-00738-7"},{"key":"948_CR83","doi-asserted-by":"publisher","unstructured":"Kun W, Yi W, Xianyun F, Shaobin W, Shidan L, Minmin C. MtDNA regulates cGAS-STING signaling pathway in adenomyosis. Free Radic Biol Med. 2024. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.03.012.","DOI":"10.1016\/j.freeradbiomed.2024.03.012"},{"key":"948_CR84","doi-asserted-by":"publisher","unstructured":"Mile S, Roohi V, Abdikarim A, Peter C, Marc G J. NLRP3 knockout enhances immune infiltration and inflammatory responses and improves survival in a burn sepsis model. Immunology. 2021;165(2):195\u2013205. https:\/\/doi.org\/10.1111\/imm.13427.","DOI":"10.1111\/imm.13427"},{"key":"948_CR85","doi-asserted-by":"publisher","unstructured":"Hannah EM, Kathrynne AW, Andrew V, Charles N V, Kiana K, Irene S, et al. Effector memory t cells induce innate inflammation by triggering DNA damage and a non-canonical STING pathway in dendritic cells. Cell Rep. 2023;42(10):113180. https:\/\/doi.org\/10.1016\/j.celrep.2023.113180.","DOI":"10.1016\/j.celrep.2023.113180"},{"key":"948_CR86","doi-asserted-by":"publisher","unstructured":"Lixiu M, Tianyu H, Yi-An Z. Mechanism a nd role of mitophagy in the development of severe infection. Cell Death Discov. 2024;10(1):88. https:\/\/doi.org\/10.1038\/s41420-024-01844-4.","DOI":"10.1038\/s41420-024-01844-4"},{"key":"948_CR87","doi-asserted-by":"publisher","unstructured":"Muzhda H, Frank B, Anne-Claire L, Lorna G, L\u00e9a P, Fabienne V, et al. Association of pronounced elevation of NET formation and nucleosome biomarkers with mortality in patients with septic shock. Ann Intensive Care. 2023;13(unknown):102. https:\/\/doi.org\/10.1186\/s13613-023-01204-y.","DOI":"10.1186\/s13613-023-01204-y"},{"key":"948_CR88","doi-asserted-by":"publisher","unstructured":"Jinfang X, Yuan R, Ying C, Huadong Z, Yang W. Inhibition of neutrophil infiltration and NETosis ameliorates sepsis-induced cardiac injury and reduces myocardial inflammation and apoptosis. Int Immunopharmacol. 2025;168(Pt 1):115862. https:\/\/doi.org\/10.1016\/j.intimp.2025.115862.","DOI":"10.1016\/j.intimp.2025.115862"},{"key":"948_CR89","doi-asserted-by":"publisher","unstructured":"Giovanni M, Alessandro M, Alice C, Irene M, Silvia S. Immune-mediated inflammatory diseases: common and different pathogenic and clinical features. Autoimmun Rev. 2023;22(10):103410. https:\/\/doi.org\/10.1016\/j.autrev.2023.103410.","DOI":"10.1016\/j.autrev.2023.103410"},{"key":"948_CR90","doi-asserted-by":"publisher","unstructured":"Dongwei Z, Biying D, Jie C, Zhenqiang Z, Weitong Z, Longxiong L, et al. Fecal microbiota transplantation modulates th17\/treg balance via JAK\/STAT pathway in ARDS rats. Adv Biol (Weinh). 2025;9(9):e00028. https:\/\/doi.org\/10.1002\/adbi.202500028.","DOI":"10.1002\/adbi.202500028"},{"key":"948_CR91","doi-asserted-by":"publisher","unstructured":"VeronikaH, Gregory F S. Group 3 innatelymphoid cells in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2024;21(6):428\u201343. https:\/\/doi.org\/10.1038\/s41575-024-00906-3.","DOI":"10.1038\/s41575-024-00906-3"},{"key":"948_CR92","doi-asserted-by":"publisher","unstructured":"Bivek B, Manisha S, Harshita S, Mohd H, Jasvinder Singh B, Puneet Kaur R, et al. Naringin: a flavanone with a multifaceted target against sepsis-associated organ injuries. Phytomedicine. 2024;130:155707. https:\/\/doi.org\/10.1016\/j.phymed.2024.155707.","DOI":"10.1016\/j.phymed.2024.155707"},{"key":"948_CR93","doi-asserted-by":"publisher","unstructured":"Izabela S, Monika P, Tomasz M G. The im munology of psoriasis-current concepts in pathogenesis. Clin Rev Allergy Immunol. 2024;66(2):164\u201391. https:\/\/doi.org\/10.1007\/s12016-024-08991-7.","DOI":"10.1007\/s12016-024-08991-7"},{"key":"948_CR94","doi-asserted-by":"publisher","unstructured":"Ritesh K, Arianne L T, V K. ROR\u03b3t protein modifications and IL-17-mediated inflammation. Trends Immunol 2021;42(11):1037\u201350. https:\/\/doi.org\/10.1016\/j.it.2021.09.005.","DOI":"10.1016\/j.it.2021.09.005"},{"key":"948_CR95","doi-asserted-by":"publisher","unstructured":"Masutaka F, Kazuhisa F, Gaku T, TakeshiN. Interleukin-17a and keratinocytes in psoriasis. Int J Mol Sci. 2020;21(4):1275. https:\/\/doi.org\/10.3390\/ijms21041275.","DOI":"10.3390\/ijms21041275"},{"issue":"8","key":"948_CR96","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/kjm2.12683","volume":"39","author":"C Wen-Cheng","year":"2023","unstructured":"Wen-Cheng C, Wen C-H, Wang M, Xiao Z-D, Zhang Z, Wu C-L, et al. IL-23\/IL-17 immune axis mediates the imiquimod-induced psoriatic inflammation by activating ACT1\/TRAF6\/TAK1\/NF-\u03bab pathway in macrophages and keratinocytes. The Kaohsiung J Med Scie. 2023;39(8):789\u2013800. https:\/\/doi.org\/10.1002\/kjm2.12683.","journal-title":"The Kaohsiung J Med Scie"},{"key":"948_CR97","doi-asserted-by":"publisher","unstructured":"Ipsita S, Piotr K, Aleksandr P, Rochelle L C, Erica S, Yue X, et al. Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation. Immunity.e7. 2024;57(7):1665\u201380. https:\/\/doi.org\/10.1016\/j.immuni.2024.04.022.","DOI":"10.1016\/j.immuni.2024.04.022"},{"key":"948_CR98","doi-asserted-by":"publisher","unstructured":"Sarah KW, Mushi L, Sakeen W K, Toshiro H, Botond Z I, Kelley K, et al. Local IL-23 is required for proliferation and retention of skin-resident memory t(h)17 cells. Sci Immunol. 2022;7(77):eabq3254. https:\/\/doi.org\/10.1126\/sciimmunol.abq3254.","DOI":"10.1126\/sciimmunol.abq3254"},{"key":"948_CR99","doi-asserted-by":"publisher","unstructured":"Jaehwan K, Jongmi L, Hyun Je K, Naoya K, Roya N, Evan D, et al. Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets. J. Allergy Clin. Immunol. 2021;148(5):1281\u201392. https:\/\/doi.org\/10.1016\/j.jaci.2021.04.021.","DOI":"10.1016\/j.jaci.2021.04.021"},{"key":"948_CR100","doi-asserted-by":"publisher","unstructured":"Yiting L, Ke X, Qingyang L, Zhenhua L, Zhenlai Z, Jiaoling C, et al. Cyclin-dependent kinase 7 promotes th17\/th1 cell differentiation in psoriasis by modulating glycolytic metabolism. The J Invest Dermatol.e11. 2021;141(11):2656\u201367. https:\/\/doi.org\/10.1016\/j.jid.2021.04.018.","DOI":"10.1016\/j.jid.2021.04.018"},{"key":"948_CR101","doi-asserted-by":"publisher","unstructured":"Kevin L, Tania P, Meng-Hua L, Sakunthala M, Rebekah J K, Laurence B, et al. Fibroblasts and macrophages cooperatet o create a pro-tumorigenic and immune resistant environment via activation of TGF-\u03b2\/IL-6 pathway in neuroblastoma. Oncoimmunology. 2022;11(1):2146860. https:\/\/doi.org\/10.1080\/2162402x.2022.2146860.","DOI":"10.1080\/2162402x.2022.2146860"},{"key":"948_CR102","doi-asserted-by":"publisher","unstructured":"Go J Y. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. J Exp Clin Cancer Res. 2020;39(1):112. https:\/\/doi.org\/10.1186\/s13046-020-01611-0.","DOI":"10.1186\/s13046-020-01611-0"},{"key":"948_CR103","doi-asserted-by":"publisher","unstructured":"Man W, Yuanzhuo Z, Kangchun X, Chao L, Hui Z, You W, et al. Cancer-associated fibroblasts in clear cell renal cell carcinoma: functional heterogeneity, tumor microenvironment crosstalk, and therapeutic opportunities. Front Immunol. 2025;16:e1617968. https:\/\/doi.org\/10.3389\/fimmu.2025.1617968.","DOI":"10.3389\/fimmu.2025.1617968"},{"key":"948_CR104","doi-asserted-by":"publisher","unstructured":"Wang Q, Yu Y, Zhuang J, Liu R, Sun C. Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment. Mol Cancer. 2025;24(1). https:\/\/doi.org\/10.1186\/s12943-025-02380-0.","DOI":"10.1186\/s12943-025-02380-0"},{"key":"948_CR105","doi-asserted-by":"publisher","unstructured":"Steve D, Stephanie C, Hannah E V, Dani el B S. New frontiers in the cGAS-STING intracellular DNA-sensing pathway. Immunity. 2024;57(4):718\u201330. https:\/\/doi.org\/10.1016\/j.immuni.2024.02.019.","DOI":"10.1016\/j.immuni.2024.02.019"},{"key":"948_CR106","doi-asserted-by":"publisher","unstructured":"Meng G, Dongjian Z, Cuihua J, Qiaomei J, Jian Z. Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-l1 expression. Biomed Pharmacother. 2023;166:115317. https:\/\/doi.org\/10.1016\/j.biopha.2023.115317.","DOI":"10.1016\/j.biopha.2023.115317"},{"key":"948_CR107","doi-asserted-by":"publisher","unstructured":"Jiawen Q, Chen W, Bo W, Jiao Y, Yuedi W, Feifei L, et al. The IFN-\u03b3\/PD-l1 axis between t cells and tumor microenvironment: hints for glioma anti-PD-1\/PD-l1 therapy. J Neuroinflammation. 2018;15(1):290. https:\/\/doi.org\/10.1186\/s12974-018-1330-2.","DOI":"10.1186\/s12974-018-1330-2"},{"key":"948_CR108","doi-asserted-by":"publisher","unstructured":"Katerina C, Alexandra C, Bence R, Vijay J, Marianne E, Aase H, et al. Tocilizumab decreases t cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL. RMD Open;2021. https:\/\/doi.org\/10.1136\/rmdopen-2021-001662.","DOI":"10.1136\/rmdopen-2021-001662"},{"key":"948_CR109","doi-asserted-by":"publisher","unstructured":"Yuxin C, Yasi D, Hao Z, Bin L, Yupei Y, Juan H, et al. Xuetongsu attenuates synovial inflammation in rheumatoid arthritis by inhibiting the IL-23\/IL-17\/NF-\u03bab inflammatory axis. Front Pharmacol. 2025;16:1615519. https:\/\/doi.org\/10.3389\/fphar.2025.1615519.","DOI":"10.3389\/fphar.2025.1615519"},{"key":"948_CR110","doi-asserted-by":"publisher","unstructured":"H M, H N, M M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatol (Oxford). 2008;47(11):1635\u201340. https:\/\/doi.org\/10.1093\/rheumatology\/ken363.","DOI":"10.1093\/rheumatology\/ken363"},{"key":"948_CR111","doi-asserted-by":"publisher","unstructured":"Erik L, Marije I K, Birgitte O, Liduine V, Christina JJ, Leo Ab C, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004. https:\/\/doi.org\/10.1002\/art.20001.","DOI":"10.1002\/art.20001"},{"key":"948_CR112","doi-asserted-by":"publisher","unstructured":"Noriko K, Kazuo O, Shinichiro S, Tomoki N, Masatsugu O, Tatsuhiko K, et al. Pathogenic conversion of foxp3+ t cells into TH17 cells in autoimmune arthritis. Nat Med. 2013;20(1):62\u20138. https:\/\/doi.org\/10.1038\/nm.3432.","DOI":"10.1038\/nm.3432"},{"key":"948_CR113","doi-asserted-by":"publisher","unstructured":"Jung-Yoon C, Ki-Yeun P, Sung-Hoon P, Sang-Il L, Seong-Kyu K. Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6\/sIL-6r-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. Arthritis Res Ther. 2013;15:R26. https:\/\/doi.org\/10.1186\/ar4162.","DOI":"10.1186\/ar4162"},{"key":"948_CR114","doi-asserted-by":"publisher","unstructured":"Monica V, Manirath K, Belgin D, Svetlana F L, Ahmed E, Emre C, et al. Agr2-associated ER stress promotes adherent-invasive e. coli dysbiosis and triggers CD103(+) dendritic cell IL-23-dependent ileocolitis. Cell Rep. 2022;41(7):111637. https:\/\/doi.org\/10.1016\/j.celrep.2022.111637.","DOI":"10.1016\/j.celrep.2022.111637"},{"key":"948_CR115","doi-asserted-by":"publisher","unstructured":"Jia W, Jingjing Y, Wenhui X, Mengna Z, Haonan T, Keyi W, et al. Escherichia coli enhances th17\/treg imbalance via TLR4\/NF-\u03bab signaling pathway in oral lichen planus. Int Immunopharmacol. 2023;119:110175. https:\/\/doi.org\/10.1016\/j.intimp.2023.110175.","DOI":"10.1016\/j.intimp.2023.110175"},{"key":"948_CR116","doi-asserted-by":"publisher","unstructured":"Silvio D, Laurent P. Are all the IL-23 block ers the same in inflammatory bowel disease? Nat Rev Gastroenterol Hepatol. 2024;21(3):138\u20139. https:\/\/doi.org\/10.1093\/oso\/9780199230716.003.0003.","DOI":"10.1093\/oso\/9780199230716.003.0003"},{"key":"948_CR117","doi-asserted-by":"publisher","unstructured":"Jiewen W, Guangbo K, Huiying L, Ario D, Haibin Y, Zelin F, et al. Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-\u03b1 and IL-23p19 bioactivities. Clin Transl Med. 2024;14(3):e1636. https:\/\/doi.org\/10.1002\/ctm2.1636.","DOI":"10.1002\/ctm2.1636"},{"key":"948_CR118","doi-asserted-by":"publisher","unstructured":"Siwei W, Wei L, Bowen W, Aihua W, Yiwen W, Wen W, et al. Traditional herbal medicine: therapeutic potential in acute gouty arthritis. J Ethnopharmacol. 2024;330:118182. https:\/\/doi.org\/10.1016\/j.jep.2024.118182.","DOI":"10.1016\/j.jep.2024.118182"},{"key":"948_CR119","doi-asserted-by":"publisher","unstructured":"Juanjuan Z, Zhongxin J, Yue S, Shu H, Yuzhang D, Xiaobao Y, et al. 3, 4-methylenedioxy-\u03b2-nitrostyrene alleviatesdextran sulfate sodium-induced mouse colitis by inhibiting the NLRP3 inflammasome. Front Pharmacol. 2022;13:866228. https:\/\/doi.org\/10.3389\/fphar.2022.866228.","DOI":"10.3389\/fphar.2022.866228"},{"key":"948_CR120","doi-asserted-by":"publisher","unstructured":"Dominik A, Maria Q, Soumya B, Nicholas I, Joanneke J, Boyd S, et al. Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance. Gut 2020. https:\/\/doi.org\/10.1136\/gutjnl-2020-321731.","DOI":"10.1136\/gutjnl-2020-321731"},{"key":"948_CR121","doi-asserted-by":"publisher","unstructured":"Matija H, Rui S, Chen H, Clara A. STAT3 and STAT5 signaling thresholds determine distinct regulation for innate receptor-induced inflammatory cytokines, and STAT3\/STAT5 disease variants modulate these outcomes. J Immunol. 2019;203(12):3325\u201338. https:\/\/doi.org\/10.4049\/jimmunol.1900031.","DOI":"10.4049\/jimmunol.1900031"},{"key":"948_CR122","doi-asserted-by":"publisher","unstructured":"Lu L, Fei L, Chunyue F, Zhenjie C, Nan Z, Jianhua M. Role of mitochondrial dysfunction in kidney disease: insights from the cGAS-STING signaling pathway. Chin Med J (Engl). 2024;137(9):1044\u201353. https:\/\/doi.org\/10.1016\/j.medj.2025.100880.","DOI":"10.1016\/j.medj.2025.100880"},{"key":"948_CR123","doi-asserted-by":"publisher","unstructured":"Imad MT, Zakariya K, Moussab D, Muhammad R, Haytham T, Mustafa A, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect. 2020;27(2):215\u201327. https:\/\/doi.org\/10.1016\/j.cmi.2021.02.024.","DOI":"10.1016\/j.cmi.2021.02.024"},{"key":"948_CR124","doi-asserted-by":"publisher","unstructured":"Haibo S, Shufeng W, Liulin L, Qin S, Taiyue L, Huixia M, et al. Mycobacterium tuberculosis hijacks host macrophages-derived interleukin 16 to block phagolysosome maturation for enhancing intracellular growth. Emerg Microbes Infect. 2024;13(1):2322663. https:\/\/doi.org\/10.1080\/22221751.2024.2322663.","DOI":"10.1080\/22221751.2024.2322663"},{"issue":"6","key":"948_CR125","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10787-019-00605-5","volume":"27","author":"YS Lee","year":"2019","unstructured":"Lee YS, Lee SY, Park SY, Lee SW, Hong KW, Kim CD. Cilostazol add-on therapy for celecoxib synergistically inhibits proinflammatory cytokines by activating IL-10 and SOCS3 in the synovial fibroblasts of patients with rheumatoid arthritis. Inflammopharmacology. 2019;27(6):1205\u201316. https:\/\/doi.org\/10.1007\/s10787-019-00605-5.","journal-title":"Inflammopharmacology"},{"key":"948_CR126","doi-asserted-by":"publisher","unstructured":"Hanxiao Y, Dong X, Jiuliang Z, Jing L, Qian W, Xinping T, et al. JAK inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol. 2020;59(3):334\u201351. https:\/\/doi.org\/10.1007\/s12016-020-08786-6.","DOI":"10.1007\/s12016-020-08786-6"},{"key":"948_CR127","doi-asserted-by":"publisher","unstructured":"Gils R, Marijke T, Kristien W, Diana C, Donovan F, Wilfried S, et al. Safety and clinical efficacy of BCMA CAR-t-cell therapy in multiple myeloma. J Hematol Oncol. 2020;13(1):164. https:\/\/doi.org\/10.1186\/s13045-020-01001-1.","DOI":"10.1186\/s13045-020-01001-1"},{"key":"948_CR128","doi-asserted-by":"publisher","unstructured":"Paula R, Niels WCJ, Kodandaram V, Ingrid P, Deeksha C, Kathleen V, et al. GPRC5d as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024;14(1):24. https:\/\/doi.org\/10.1038\/s41408-024-01018-6.","DOI":"10.1038\/s41408-024-01018-6"},{"key":"948_CR129","doi-asserted-by":"publisher","unstructured":"Pooneh S, Sheena S, Diane W, Hoi-Kei L, Akos C, Anne H, et al. Impact of treatment modality and route of administration on cytokine release syndrome in relapsed or refractory multiple myeloma: a meta-analysis. Clin Pharmacol Ther. 2024;115(6):1258\u201368. https:\/\/doi.org\/10.1002\/cpt.3223.","DOI":"10.1002\/cpt.3223"},{"key":"948_CR130","doi-asserted-by":"publisher","unstructured":"Joseph AP, Lindsey S, Joseph T C, Jodi A G, Jonathan H D, Bonnie B D, et al. PD-l1-PD-1 interactions limit effector regulatory t cell populations at homeostasis and during infection. Nat Immunol. 2022;23(5):743\u201356. https:\/\/doi.org\/10.1101\/2020.12.09.416990.","DOI":"10.1101\/2020.12.09.416990"},{"key":"948_CR131","doi-asserted-by":"publisher","unstructured":"Laura P, Cristina G, Chiara N, Giovanna B, Emanuele R, Carmine N, et al. Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. Faseb J. 2007;21(7):1393\u20131402. https:\/\/doi.org\/10.1096\/fj.202300970.","DOI":"10.1096\/fj.202300970"},{"key":"948_CR132","doi-asserted-by":"publisher","unstructured":"Lihi R, Matthias P K, Michal P, Nofar S, Stav R, Keren D, et al. The survival and function of IL-10-producing regulatory b cells are negatively controlled by SLAMF5. Nat Commun. 2021;12(1):1893. https:\/\/doi.org\/10.1038\/s41467-021-22230-z.","DOI":"10.1038\/s41467-021-22230-z"},{"key":"948_CR133","doi-asserted-by":"publisher","unstructured":"Chaoran L, Gang W, Pulavendran S, Ricardo N R, Yanbo Z, Christophe B, et al. Interferon-\u03b1-producing plasmacytoid dendritic cells drive the loss of adipose tissue regulatory t cells during obesity. Cell Metab 2021. https:\/\/doi.org\/10.1016\/j.cmet.2021.06.007.","DOI":"10.1016\/j.cmet.2021.06.007"},{"key":"948_CR134","doi-asserted-by":"publisher","unstructured":"Xinyu W, Qingbin H, Lining W, Chengzhilin L, Wenyu Z, Zhonghou R, et al. Acid responsive molybdenum (mo)-based nanoparticles inhibit the cGAS-STING signaling pathway for sepsis therapy. Biomater Sci. 2025;13(9):2410\u201321. https:\/\/doi.org\/10.1039\/d5bm00007f.","DOI":"10.1039\/d5bm00007f"},{"key":"948_CR135","doi-asserted-by":"publisher","unstructured":"Zhixiong Z, Xian W, Qiang H, Zhonghua S, Xiaofeng C, Jialin W, et al. Discovery of STING antagonists targeting cGAS-STING pathway to alleviate IMQ-induced psoriasis-like dermatitis. Eur J Pharm Sci. 2025;210:107091. https:\/\/doi.org\/10.1016\/j.ejps.2025.107091.","DOI":"10.1016\/j.ejps.2025.107091"},{"key":"948_CR136","doi-asserted-by":"publisher","unstructured":"M KB, J X, A V, M PV. Cascade of immun e mechanism and consequences of inflammatory disorders. Phytomedicine. 2021;91:153712. https:\/\/doi.org\/10.1016\/j.phymed.2021.153712.","DOI":"10.1016\/j.phymed.2021.153712"},{"key":"948_CR137","doi-asserted-by":"publisher","unstructured":"K V. Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomo dulatory targets. Int Immunopharmacol. 2020;89:107087. https:\/\/doi.org\/10.1016\/j.intimp.2020.107087.","DOI":"10.1016\/j.intimp.2020.107087"},{"key":"948_CR138","doi-asserted-by":"publisher","unstructured":"Rodger PM. Selectins: initiators of leuco cyte adhesion and signalling at the vascular wall. Cardiovasc Res. 2015;107(3):331\u20139. https:\/\/doi.org\/10.1093\/cvr\/cvv154.","DOI":"10.1093\/cvr\/cvv154"},{"key":"948_CR139","doi-asserted-by":"publisher","unstructured":"Katrin R, Anca-Laura A, Winfried P, Veronika G. Negative regulation of ATP-induced inflammasome activation and cy tokine secretion by acute-phase proteins: a mini review. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.981276.","DOI":"10.3389\/fphar.2022.981276"},{"key":"948_CR140","doi-asserted-by":"publisher","unstructured":"Emily HS, Xinyi W, Swathi B, Manish J B, Paul L B, Sundeep G K. The role of the anti-inflammatory cytokine interleukin-10 in tissue fibrosis. Adv Wound Care (New Rochelle). 2020;9(4):184\u201398. https:\/\/doi.org\/10.1089\/wound.2019.1032.","DOI":"10.1089\/wound.2019.1032"},{"key":"948_CR141","doi-asserted-by":"publisher","unstructured":"Rongli X, Dan T, Boke L, Guohui X, Fangchen G, Qiyao Z, et al. Acute respiratory distress syndrome (ARDS): from mechan istic insights to therapeutic strategies. MedComm. 2020). 2025;6(2):e70074. https:\/\/doi.org\/10.1002\/mco2.70074.","DOI":"10.1002\/mco2.70074"},{"key":"948_CR142","doi-asserted-by":"publisher","unstructured":"Thomas AW, Kevin M V. Macrophages intissue repair, regeneration, and fibrosis. Immunity. 2016;44(3):450\u201362. https:\/\/doi.org\/10.1016\/j.immuni.2016.02.015.","DOI":"10.1016\/j.immuni.2016.02.015"},{"key":"948_CR143","doi-asserted-by":"publisher","unstructured":"Toshihisa A. Inflammatory mechanisms of cardiovascular remodeling. Circ J. 2018;82(3):629-35. https:\/\/doi.org\/10.1253\/circj.CJ-18-0063.","DOI":"10.1253\/circj.CJ-18-0063"},{"key":"948_CR144","doi-asserted-by":"publisher","unstructured":"Lam CT, Elke R, Dora S, Ulrike W, Jingru S, Sascha G, et al. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. J. Allergy Clin. Immunol. 2020;145(5):1406\u201315. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.047.","DOI":"10.1016\/j.jaci.2019.11.047"},{"key":"948_CR145","doi-asserted-by":"publisher","unstructured":"Zhengping H, Kailey E B, Liang C, Yan D, Holly W, Evan E H, et al. Type i interferon signature and cycling lymphocytes in macrophage activation syndrome. J. Clin. Invest. 2023;133(22):e165616. https:\/\/doi.org\/10.7554\/elife.106814.2.sa1.","DOI":"10.7554\/elife.106814.2.sa1"},{"key":"948_CR146","doi-asserted-by":"publisher","unstructured":"Patrycja S, Anna S, Piotr D, Bartosz K. M olecular basis of chronic intestinal wall fibrosis in inflammatory bowel diseases. Int J Mol Sci. 2025;26(12):5754. https:\/\/doi.org\/10.3390\/ijms26125754.","DOI":"10.3390\/ijms26125754"},{"key":"948_CR147","doi-asserted-by":"publisher","unstructured":"Theresa VR, Daniel TM, Jerrold MO, Mar c Y D. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31\u201355. https:\/\/doi.org\/10.1016\/j.immuni.2021.12.013.","DOI":"10.1016\/j.immuni.2021.12.013"},{"key":"948_CR148","doi-asserted-by":"publisher","unstructured":"CL, F C, B JF. The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation. Curr Top Microbiol Immunol. 1991;174:121\u201334. https:\/\/doi.org\/10.1007\/978-3-642-50998-8_9.","DOI":"10.1007\/978-3-642-50998-8_9"},{"issue":"1 Pt 2","key":"948_CR149","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1097\/00007890-199312000-00045","volume":"25","author":"JL Ferrara","year":"1993","unstructured":"Irene Maeve R, David S G, Victoria M, Susan E M, A HD, Owen A R. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9:586. https:\/\/doi.org\/10.1097\/00007890-199312000-00045.","journal-title":"Transpl Proc"},{"key":"948_CR150","doi-asserted-by":"publisher","unstructured":"Lan Y, Xueru X, Zikun T, Jinrong F, Damo X, Yufeng Z. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther 2021. https:\/\/doi.org\/10.1038\/s41392-021-00679-0.","DOI":"10.1038\/s41392-021-00679-0"},{"key":"948_CR151","doi-asserted-by":"publisher","unstructured":"Alexandra F. Sleep deprivation whips up cytokine storm. Nat Rev Immunol. 2023;24(1):2\u20132. https:\/\/doi.org\/10.1038\/s41577-023-00980-9.","DOI":"10.1038\/s41577-023-00980-9"},{"key":"948_CR152","doi-asserted-by":"publisher","unstructured":"Haixia K, Ting L, Yuanyuan W, Wenjuan B, Yan L, Jing W. Neutrophil-macrophage communication via extracellular vesicle transfer promotes itaconate accumulation and ameliorates cytokine storm syndrome. Cell Mol Immunol. 2024;21(Unknown):689\u2013706. https:\/\/doi.org\/10.1038\/s41423-024-01174-6.","DOI":"10.1038\/s41423-024-01174-6"},{"key":"948_CR153","doi-asserted-by":"publisher","unstructured":"Abdusalam Abdullah A, Nur AimiLiyana A, Nur Izah A, Razif A, Hasnah B, Maizaton Atmadini A, et al. Immunomodulating phytochemicals: an insight into their potential use in cytokine storm situations. Adv Pharm Bull. 2024. https:\/\/doi.org\/10.34172\/apb.2024.001.","DOI":"10.34172\/apb.2024.001"},{"issue":"7","key":"948_CR154","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","volume":"94","author":"U Winkler","year":"1999","unstructured":"Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with b-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-c2b8). Blood. 1999;94(7):2217\u201324. https:\/\/doi.org\/10.1182\/blood.V94.7.2217.419k02_2217_2224.","journal-title":"Blood"},{"key":"948_CR155","doi-asserted-by":"publisher","unstructured":"Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121, 121(26(26):5154\u201357): 1441. Blood 2016, https:\/\/doi.org\/10.1182\/blood-2013-02-485623.","DOI":"10.1182\/blood-2013-02-485623"},{"key":"948_CR156","doi-asserted-by":"publisher","unstructured":"Sjoukje Jc V, David M D, Scott W, Julie F, Jane K S, Jerome B, et al. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human t cells: identifying a window of therapeutic opportunity? J Immunol. 2013. https:\/\/doi.org\/10.1016\/j.cyto.2008.07.147.","DOI":"10.1016\/j.cyto.2008.07.147"},{"key":"948_CR157","doi-asserted-by":"publisher","unstructured":"Lee F, Anneli C, Cristina F, Daniel M A, Shiranee S. The mechanism of superantigen-mediated toxic shock: not a simple th1 cytokine storm. J Immunol. 2005;175(10):6870\u201377. https:\/\/doi.org\/10.4049\/jimmunol.175.10.6870.","DOI":"10.4049\/jimmunol.175.10.6870"},{"key":"948_CR158","doi-asserted-by":"publisher","unstructured":"Cecilia G, Charles A D, Alberto M. The in terleukin-1 family: back to the future. Immunity. 2013;39(6):1003\u201318. https:\/\/doi.org\/10.1016\/j.immuni.2013.11.010.","DOI":"10.1016\/j.immuni.2013.11.010"},{"key":"948_CR159","doi-asserted-by":"publisher","unstructured":"Fabio M, Virginie P, Annick M, Aubry T, J\u00fc rg T. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237\u201341. https:\/\/doi.org\/10.1038\/nature04516.","DOI":"10.1038\/nature04516"},{"key":"948_CR160","doi-asserted-by":"publisher","unstructured":"Daniel F, James EV. Pyroptosis versus n ecroptosis: similarities, differences, and crosstalk. Cell Death Differ. 2018;26:99\u2013114. https:\/\/doi.org\/10.1038\/s41418-018-0212-6.","DOI":"10.1038\/s41418-018-0212-6"},{"key":"948_CR161","doi-asserted-by":"publisher","unstructured":"Charles AD, Daniela N, Soohyun K, Gilles K. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013;4. https:\/\/doi.org\/10.3389\/fimmu.2013.00289.","DOI":"10.3389\/fimmu.2013.00289"},{"key":"948_CR162","doi-asserted-by":"publisher","unstructured":"Mark G, Kathryn S T, Daniel A K, Raphael H. Hypocomplementemia associated with macrophage activation syndrome insystemic juvenile idiopathic arthritis and adult onset still\u2019s disease: 3 cases. J Rheumatol. 2011;38(2):396\u20137. https:\/\/doi.org\/10.3899\/jrheum.100833.","DOI":"10.3899\/jrheum.100833"},{"key":"948_CR163","doi-asserted-by":"publisher","unstructured":"CAD. Proinflammatory cytokines. Chest. 2000;118(2):503\u20138. https:\/\/doi.org\/10.1378\/chest.118.2.503.","DOI":"10.1378\/chest.118.2.503"},{"key":"948_CR164","doi-asserted-by":"publisher","unstructured":"Anwei C, Haiqing Y, Caijing H, Wenliang W, Yaoqi T, Xiangyan C. Polyphenols from blueberries modulate inflammation cytokines in LPS-induced RAW264.7 macrophages. Int J Biol Macromol. 2014;69:382\u20137. https:\/\/doi.org\/10.1016\/j.ijbiomac.2014.05.071.","DOI":"10.1016\/j.ijbiomac.2014.05.071"},{"key":"948_CR165","doi-asserted-by":"publisher","first-page":"621931","DOI":"10.3389\/fimmu.2020.621931","volume":"11","author":"B Van Den Eeckhout","year":"2021","unstructured":"Van Den Eeckhout B, Tavernier J, Gerlo S. Interleukin-1 as innate mediator of t cell immunity. Front. Immunol. 2021;11:621931. https:\/\/doi.org\/10.3389\/fimmu.2020.621931.","journal-title":"Front. Immunol"},{"issue":"6","key":"948_CR166","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1073\/pnas.1206048110","volume":"110","author":"J Chang","year":"2013","unstructured":"Chang J, Burkett PR, Borges CM, Kuchroo VK, Turka LA, Chang C. MyD88 is essential to sustain mTOR activation necessary to promote t helper 17 cell proliferation by linking IL-1 and IL-23 signaling. Proc Natl Acad Sci USA. 2013;110(6):2270\u201375. https:\/\/doi.org\/10.1073\/pnas.1206048110.","journal-title":"Proc Natl Acad Sci USA"},{"key":"948_CR167","doi-asserted-by":"publisher","unstructured":"Lin WW, Yi Z, Stunz LL, Maine CJ, Sherman LA, Bishop GA. The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in b cells to limit plasma cell development. Sci Signal. 2015;8(392):ra88. https:\/\/doi.org\/10.1126\/scisignal.aaa5157.","DOI":"10.1126\/scisignal.aaa5157"},{"issue":"11","key":"948_CR168","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1084\/jem.20111504","volume":"209","author":"A Karnowski","year":"2012","unstructured":"Karnowski A, Chevrier S, Belz GT, Mount A, Emslie D, D\u2019Costa K, et al. B and t cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, oct2 and OBF-1. J Exp Med. 2012;209(11):2049\u201364. https:\/\/doi.org\/10.1084\/jem.20111504.","journal-title":"J Exp Med"},{"issue":"14","key":"948_CR169","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.3390\/ijms21145085","volume":"21","author":"P Guan","year":"2020","unstructured":"Guan P, Schaub R, Nichols KE, Das R. Combination of NKT14m and low dose IL-12 promotes invariant natural killer t cell IFN-\u03b3 production and tumor control. IJMS. 2020;21(14):5085. https:\/\/doi.org\/10.3390\/ijms21145085.","journal-title":"IJMS"},{"issue":"45","key":"948_CR170","doi-asserted-by":"publisher","first-page":"11585","DOI":"10.1073\/pnas.1804556115","volume":"115","author":"MF Krummel","year":"2018","unstructured":"Krummel MF, Mahale JN, Uhl LFK, Hardison EA, Mujal AM, Mazet JM, et al. Paracrine costimulation of IFN-\u03b3 signaling by integrins modulates CD8 t cell differentiation. Proc Natl Acad Sci USA. 2018;115(45):11585\u201390. https:\/\/doi.org\/10.1073\/pnas.1804556115.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"948_CR171","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/ni1254","volume":"6","author":"LE Harrington","year":"2005","unstructured":"Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17\u2013producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123\u201332. https:\/\/doi.org\/10.1038\/ni1254.","journal-title":"Nat Immunol"},{"key":"948_CR172","doi-asserted-by":"publisher","unstructured":"Wan-Wan L, Michael K. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007;117(5):1175\u201383. https:\/\/doi.org\/10.1172\/JCI31537.","DOI":"10.1172\/JCI31537"},{"key":"948_CR173","doi-asserted-by":"crossref","unstructured":"Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes.Life Sci. 2000;67(3), 291\u2013300. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320500006226.","DOI":"10.1016\/S0024-3205(00)00622-6"},{"key":"948_CR174","doi-asserted-by":"publisher","unstructured":"Sieglinde K, Thomas N, Michael W. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond). 2004;108(3):205\u2013213. https:\/\/doi.org\/10.1042\/cs20040174.","DOI":"10.1042\/cs20040174"},{"key":"948_CR175","doi-asserted-by":"publisher","unstructured":"Viviani M, Izabela G, Angelica Thomaz V. Mechanisms by which the gut microbiota influences cytokine production and modulates host inflammatory responses. J Interferon Cytokine Res. 2019;39(7):393\u2013409. https:\/\/doi.org\/10.1089\/jir.2019.0011.","DOI":"10.1089\/jir.2019.0011"},{"key":"948_CR176","doi-asserted-by":"publisher","unstructured":"Chin-Hsien L, Chieh-Chang C, Han-Lin C, Jyh-Ming L, Chih-Min C, Tzu-Pin L, et al. Altered gut microbiota and inflammatory cytokine responses in patients with parkinson\u2019s disease. J Neuroinflammation. 2019;16(1):129. https:\/\/doi.org\/10.1186\/s12974-019-1528-y.","DOI":"10.1186\/s12974-019-1528-y"},{"key":"948_CR177","doi-asserted-by":"publisher","unstructured":"Irene Maeve R, David S G, Victoria M, Susan E M, A HD, Owen A R. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9:586. https:\/\/doi.org\/10.3389\/fimmu.2018.00586.","DOI":"10.3389\/fimmu.2018.00586"},{"issue":"6337","key":"948_CR178","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1126\/science.aal3535","volume":"356","author":"WKE Ip","year":"2017","unstructured":"Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Sci (New Y, N.Y.). 2017;356(6337):513\u201319. https:\/\/doi.org\/10.3410\/f.727577124.793533156.","journal-title":"Sci (New Y, N.Y.)"},{"key":"948_CR179","doi-asserted-by":"publisher","unstructured":"Wang L, Liu J, Talebian F, Liu Z, Yu L, Bai X. IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4 + T cells and promoting CTL persistence in a murine model of plasmacytoma. Oncoimmunology. 2015;4(7):e1014232. https:\/\/doi.org\/10.1080\/2162402X.2015.1014232.","DOI":"10.1080\/2162402X.2015.1014232"},{"issue":"3","key":"948_CR180","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jaci.2014.07.041","volume":"135","author":"B Stanic","year":"2015","unstructured":"Stanic B, van de Veen W, Wirz OF, R\u00fcckert B, Morita H, S\u00f6llner S, et al. IL-10\u2013overexpressing B cells regulate innate and adaptive immune responses. J Allergy Clin Immunol Pract. 2015;135(3):771\u201380.e8. https:\/\/doi.org\/10.1016\/j.jaci.2014.07.041.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"948_CR181","doi-asserted-by":"publisher","unstructured":"Kim HS, Kim A, Kim DK, Kim HW, Park YH, Jang GH, et al. Interleukin-10\u2013producing CD5 + B cells inhibit mast cells during immunoglobulin E\u2013mediated allergic responses. Sci Signal. 2015;8(368):ra28. https:\/\/doi.org\/10.1126\/scisignal.2005861.","DOI":"10.1126\/scisignal.2005861"},{"issue":"7","key":"948_CR182","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3390\/cells10071615","volume":"10","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Kurashima Y. Two sides of the coin: mast cells as a key regulator of allergy and acute\/chronic inflammation. Cells. 2021;10(7):1615. https:\/\/doi.org\/10.3390\/cells10071615.","journal-title":"Cells"},{"key":"948_CR183","doi-asserted-by":"publisher","unstructured":"Peleg R, Yaron C, Idan C. Biologics for ta rgeting inflammatory cytokines, clinical uses, and limitations. Int J Cell Biol. 2017;2016:9259646. https:\/\/doi.org\/10.1155\/2016\/9259646.","DOI":"10.1155\/2016\/9259646"},{"key":"948_CR184","doi-asserted-by":"publisher","unstructured":"M A, A ML, H A, P G, M G, F G, et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol. 1995;15(5):266\u201373. https:\/\/doi.org\/10.1007\/bf01540884.","DOI":"10.1007\/bf01540884"},{"key":"948_CR185","doi-asserted-by":"publisher","unstructured":"Michael C, Beyond RMS, TNF. TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13(4):217-33. https:\/\/doi.org\/10.1038\/nrrheum.2009.1.","DOI":"10.1038\/nrrheum.2009.1"},{"key":"948_CR186","doi-asserted-by":"publisher","unstructured":"Yoichiro I, Harumichi I, Shinobu S, Susum u N. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149\u201362. https:\/\/doi.org\/10.1016\/j.immuni.2011.02.012.","DOI":"10.1016\/j.immuni.2011.02.012"},{"key":"948_CR187","doi-asserted-by":"publisher","unstructured":"Leticia M, Sarah L G. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb Perspect Biol. 2017;10(4):a028522. https:\/\/doi.org\/10.1101\/cshperspect.a028522.","DOI":"10.1101\/cshperspect.a028522"},{"key":"948_CR188","doi-asserted-by":"publisher","unstructured":"David W. The tumor necrosis factor famil y: family conventions and private idiosyncrasies. Cold Spring Harb Perspect Biol. 2017;10(10):a028431. https:\/\/doi.org\/10.1101\/cshperspect.a028431.","DOI":"10.1101\/cshperspect.a028431"},{"key":"948_CR189","doi-asserted-by":"publisher","unstructured":"Danping Z, Timur L, Eran E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov 2020;6(36). https:\/\/doi.org\/10.1038\/s41421-020-0167-x.","DOI":"10.1038\/s41421-020-0167-x"},{"key":"948_CR190","doi-asserted-by":"publisher","unstructured":"Arwa AA, Fatimah SA, Ahmed Ali A. Pro-inflammatory and anti-inflammatory interleukins in infectious diseases: a comprehensive review. Trop Med Infect Dis. 2024;9(1):13. https:\/\/doi.org\/10.3390\/tropicalmed9010013.","DOI":"10.3390\/tropicalmed9010013"},{"issue":"7","key":"948_CR191","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3390\/biom10071017","volume":"10","author":"C Porro","year":"2020","unstructured":"Porro C, Cianciulli A, Panaro MA. The regulatory role of IL-10 in neurodegenerative diseases. Biomolecules. 2020;10(7):1017. https:\/\/doi.org\/10.3390\/biom10071017.","journal-title":"Biomolecules"},{"key":"948_CR192","doi-asserted-by":"publisher","unstructured":"Yi S, Jiangjun M, Dongfang L, Pinggan L, Xiaolin Z, Yu L, et al. Interleukin-10 inhibits interleukin-1\u03b2 production and inflammasome activation of microglia in epileptic seizures. J Neuroinflammation. 2019;16(1). https:\/\/doi.org\/10.1186\/s12974-019-1452-1.","DOI":"10.1186\/s12974-019-1452-1"},{"key":"948_CR193","doi-asserted-by":"publisher","unstructured":"Ilkka S J. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;9:888. https:\/\/doi.org\/10.3389\/fimmu.2018.00888.","DOI":"10.3389\/fimmu.2018.00888"},{"key":"948_CR194","doi-asserted-by":"publisher","unstructured":"Milena I, Sylwia B, Katarzyna B. Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis. Cells 2021;10(11):3000. https:\/\/doi.org\/10.3390\/cells10113000.","DOI":"10.3390\/cells10113000"},{"key":"948_CR195","doi-asserted-by":"publisher","unstructured":"Petra B, Thordis H, Eva B, Marie R, Matthew G B, Svenja K, et al. Human anti-fungal th17 immunity and pathology relyon cross-reactivity against candida albicans. Cell. 2019;176(6):1340\u201355.e15. https:\/\/doi.org\/10.1016\/j.cell.2019.01.041.","DOI":"10.1016\/j.cell.2019.01.041"},{"key":"948_CR196","doi-asserted-by":"publisher","unstructured":"K SA, G SL, K JK. Th17 cells at the cross roads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2009;2(5):403\u201311. https:\/\/doi.org\/10.1038\/mi.2009.100.","DOI":"10.1038\/mi.2009.100"},{"key":"948_CR197","doi-asserted-by":"publisher","unstructured":"Bhalchandra M. Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: its implications in cancer immunotherapy. SAGE Open Med; 2022. https:\/\/doi.org\/10.1177\/20503121211069012.","DOI":"10.1177\/20503121211069012"},{"key":"948_CR198","doi-asserted-by":"publisher","unstructured":"Yi Xin S, Qing Yang Y, Xiao Xiao T. Role of interleukins in the pathogenesis of pulmonary fibrosis. Cell Death Discov. 2021;7(1). https:\/\/doi.org\/10.1038\/s41420-021-00437-9.","DOI":"10.1038\/s41420-021-00437-9"},{"key":"948_CR199","doi-asserted-by":"publisher","unstructured":"Daniel A, Andreas K, Kastriot K, Christian D, Maxime D, Iain B M, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis. 2022;82(6):773\u201387. https:\/\/doi.org\/10.1136\/ard-2022-222784.","DOI":"10.1136\/ard-2022-222784"},{"key":"948_CR200","doi-asserted-by":"publisher","unstructured":"Anastasia D, Tiago T, Ronald V. Emergin g oral therapies for the treatment of psoriasis: a review of pipeline agents. Pharmaceutics. 2024;16(1):111. https:\/\/doi.org\/10.3390\/pharmaceutics16010111.","DOI":"10.3390\/pharmaceutics16010111"},{"key":"948_CR201","doi-asserted-by":"publisher","unstructured":"Azucena S, Cristian H, Marjolijn D, William F, Dermot M, Severine V, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(6):323\u20137. https:\/\/doi.org\/10.1038\/s41575-020-0273-0.","DOI":"10.1038\/s41575-020-0273-0"},{"key":"948_CR202","doi-asserted-by":"publisher","unstructured":"Miguel Q, Jeannie L, Shabnam R. Hazards of the cytokine storm and cytokine-targeted therapy in patients with COVID-19: review. J Med Internet Res. 2020;22(8):e20193. https:\/\/doi.org\/10.2196\/20193.","DOI":"10.2196\/20193"},{"key":"948_CR203","doi-asserted-by":"publisher","unstructured":"John GR, Kamyar K, Mandeep R M, Carl J L, Youssef R, Donald N F. Pharmaco-immunomodulatory therapy in COVID-19. Drugs 2020. https:\/\/doi.org\/10.1007\/s40265-020-01367-z.","DOI":"10.1007\/s40265-020-01367-z"},{"key":"948_CR204","doi-asserted-by":"publisher","unstructured":"Jae Seok K, Jun Young L, Jae Won Y, Keum Hwa L, Maria E, Wladimir S, et al. Immunopathogenesis and treatment of c ytokine storm in COVID-19. Theranostics 2021. https:\/\/doi.org\/10.7150\/thno.49713.","DOI":"10.7150\/thno.49713"},{"key":"948_CR205","doi-asserted-by":"publisher","unstructured":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)00676-0.","DOI":"10.1016\/S0140-6736(21)00676-0"},{"key":"948_CR206","doi-asserted-by":"publisher","unstructured":"Min Z, Manman L, Yangzan O, Qin H, Mingmin L, Xiangdong Y, et al. Infliximab for patients with moderate to severely active ulcerative colitis: an updated meta-analysis of randomized controlled trials. BMC Gastroenterol. 2025;25(1), 458. https:\/\/doi.org\/10.1186\/s12876-025-04065-w.","DOI":"10.1186\/s12876-025-04065-w"},{"key":"948_CR207","doi-asserted-by":"publisher","unstructured":"RK, G M, G L, B A, Z Z, K I, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2016;31(3):507\u201317. https:\/\/doi.org\/10.1111\/jdv.14015.","DOI":"10.1111\/jdv.14015"},{"key":"948_CR208","doi-asserted-by":"publisher","unstructured":"Susanne H, Kjell ErikJulius H, Marianne Baastrup S, Anne-Sofie B, Johannes Martin S, Sofie Lock J, et al. Clinical response and remission in patients treated with dupilumab for severe asthma: results from the nationwide Danish severe asthma register. Respir Med. 2025;245:108203. https:\/\/doi.org\/10.1016\/j.rmed.2025.108203.","DOI":"10.1016\/j.rmed.2025.108203"},{"key":"948_CR209","doi-asserted-by":"publisher","unstructured":"Joana R, Mafalda S, Maria Manuela E, Paula M, Catarina A, Silvio D, et al. Impact of crohn\u2019s disease therapies on histology in randomized controlled trials: systematic review with meta-analysis. Inflamm Bowel Dis. 2022;29(8):1231\u201343. https:\/\/doi.org\/10.1093\/ibd\/izac203.","DOI":"10.1093\/ibd\/izac203"},{"key":"948_CR210","doi-asserted-by":"publisher","unstructured":"SB, M A, L C, G K, L J, P L, et al. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020;34(12):2830\u201338. https:\/\/doi.org\/10.1111\/jdv.16521.","DOI":"10.1111\/jdv.16521"},{"key":"948_CR211","doi-asserted-by":"publisher","unstructured":"M H, S J, K A, B R, C M, M R, et al. Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study. Arthritis Care Res (Hoboken). 2017;69(7):1020\u201329. https:\/\/doi.org\/10.1002\/acr.23233.","DOI":"10.1002\/acr.23233"},{"key":"948_CR212","doi-asserted-by":"publisher","unstructured":"L MG, G KB, G G, Z L, P C. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2019;34(2):301\u2013309. https:\/\/doi.org\/10.1111\/jdv.15921.","DOI":"10.1111\/jdv.15921"},{"key":"948_CR213","doi-asserted-by":"publisher","unstructured":"Paulina N, Rodrigo Q, Andres J Y. Safety of janus kinase inhibitors in inflammatory bowel diseases. Drugs. 2023;83(4):299\u2013314. https:\/\/doi.org\/10.1007\/s40265-023-01840-5.","DOI":"10.1007\/s40265-023-01840-5"},{"key":"948_CR214","doi-asserted-by":"publisher","unstructured":"E EW, Athimalaipet V R, Cynthia E K, Stephanie D, Ran L, Maria LuciaB P, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on i nvasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;118:110601. https:\/\/doi.org\/10.1016\/s2213-2600(22)00006-6.","DOI":"10.1016\/s2213-2600(22)00006-6"},{"key":"948_CR215","doi-asserted-by":"publisher","unstructured":"Roy F, Jerzy S, Sara K P, Patrick D, Louis B, Xianwei B, et al. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study. RMD Open; 2024;10(2):e004007. https:\/\/doi.org\/10.1136\/rmdopen-2023-004007.","DOI":"10.1136\/rmdopen-2023-004007"},{"key":"948_CR216","doi-asserted-by":"publisher","unstructured":"Bita S, Joseph A C, Winn W, Richard L A C, Huaqing Z, Charles A D, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2015;44(2):275\u201381. https:\/\/doi.org\/10.1097\/CCM.0000000000001402.","DOI":"10.1097\/CCM.0000000000001402"},{"key":"948_CR217","doi-asserted-by":"publisher","unstructured":"Ana L, Paula P, Sophia C, Pamela C, Peter S L, Alice S, et al. Teplizumab induces persistent changes in the antigen-specificrepertoire in individuals at risk for type 1 diabetes. J. Clin. Invest. 2024;134(18). https:\/\/doi.org\/10.1172\/JCI177492.","DOI":"10.1172\/JCI177492"},{"key":"948_CR218","doi-asserted-by":"publisher","unstructured":"Antonio A, Stefano T, Carlo M, Jordana K, Benjamin W V, Charles A D. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126(9):1260\u201380. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.315937.","DOI":"10.1161\/CIRCRESAHA.120.315937"},{"key":"948_CR219","doi-asserted-by":"publisher","unstructured":"Jacob AK, Stephanie GD, Franz OS, James CY, Marybeth SH, Udai SK, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the national cancer institute between 1986 and 2006. Cancer. 2008;26(S1):13\u20137. https:\/\/doi.org\/10.1002\/cncr.23552.","DOI":"10.1002\/cncr.23552"},{"key":"948_CR220","doi-asserted-by":"publisher","unstructured":"Yifei H, Jing T, Qiao X, Zenghui F, Rongqing L, Mengxuan Y, et al. Role of pyruvate kinase m2 in regulating sepsis (review). Mol Med Rep. 2024;30(4). https:\/\/doi.org\/10.3892\/mmr.2024.13309.","DOI":"10.3892\/mmr.2024.13309"},{"key":"948_CR221","doi-asserted-by":"publisher","unstructured":"Robert MG, Karina KS, Emeline J, Jessica M S, Christian M M, Janelle S A. Fluoxetine promotes IL-10-dependent metabolic defenses to protect from sepsis-induced lethality. Sci Adv. 2025;11(7). https:\/\/doi.org\/10.1126\/sciadv.adu4034.","DOI":"10.1126\/sciadv.adu4034"},{"key":"948_CR222","doi-asserted-by":"publisher","unstructured":"Ian GG, Ashley LR, Tyler JS, Vincent AV, Jenna CC, Patrick MK, et al. Exploratory assessment of the effect of systemic administration of soluble glycoprotein 130 on cognitive performance and chemokine levels in a mouse model of experimental traumatic brain injury. J Neuroinflammation. 2024;21(1). https:\/\/doi.org\/10.1186\/s12974-024-03129-0.","DOI":"10.1186\/s12974-024-03129-0"},{"key":"948_CR223","doi-asserted-by":"publisher","unstructured":"Si-Yuan C, Ya-Ping L, Yi-Ping Y, Hong-Rui Z, Zi-Jian S, Qi-Qi L, et al. Theaflavin mitigates acute gouty peritonitis and septic organ injury in mice by suppressing NLRP3 inflammasome assembly. Acta Pharmacol Sin. 2023;44(10):2019\u201336. https:\/\/doi.org\/10.1038\/s41401-023-01105-7.","DOI":"10.1038\/s41401-023-01105-7"},{"key":"948_CR224","doi-asserted-by":"publisher","unstructured":"Hongfang F, Jiajia C, Haitao W, Yufang C, Zhengqiang Z, Qiuping Z, et al. Roflumilast reverses polymicrobial sepsis-induced liver damage by inhibiting inflammation in mice. Lab Invest. 2017;97(9):1008\u201319. https:\/\/doi.org\/10.1038\/labinvest.2017.59.","DOI":"10.1038\/labinvest.2017.59"},{"key":"948_CR225","doi-asserted-by":"publisher","unstructured":"Fuquan W, Min W, Jingxu W, Ming C, Shujun S, Shanglong Y, et al. Maresin1 ameliorates sepsis-associated lung injury by inhibiting the activation of the JAK2\/STAT3 and MAPK\/NF-\u03bab signaling pathways. Microb Pathog 2020;148:104468. https:\/\/doi.org\/10.1016\/j.micpath.2020.104468.","DOI":"10.1016\/j.micpath.2020.104468"},{"key":"948_CR226","doi-asserted-by":"publisher","unstructured":"Kevin P, Hizra F, Veera ChandraSekharreddy C, Huihong X, Chong-Xian P, Zheng Z. CAR race to cancer immunotherapy: from CAR t, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1). https:\/\/doi.org\/10.1186\/s13046-022-02327-z.","DOI":"10.1186\/s13046-022-02327-z"},{"key":"948_CR227","doi-asserted-by":"publisher","unstructured":"Joshua SD, David F, Emma P, Craig G, Michael B. Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev. 2020;33(3). https:\/\/doi.org\/10.1128\/CMR.00035-19.","DOI":"10.1128\/CMR.00035-19"},{"key":"948_CR228","doi-asserted-by":"publisher","unstructured":"Michael JM, Jeffrey MC, Matthew DV, William D. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol. 2020;86(5):1080-91. https:\/\/doi.org\/10.1016\/j.jaad.2020.12.010.","DOI":"10.1016\/j.jaad.2020.12.010"},{"key":"948_CR229","doi-asserted-by":"publisher","unstructured":"Ayrton B, Behzad A, Charlene M, Lili Z, Sarvarinder G, Andrew I, et al. Comprehensive review of early and latetoxicities in CAR t-cell therapy and bispecific antibody treatments for hematologic malignancies. Cancers (Basel). 2025;17(2):282. https:\/\/doi.org\/10.3390\/cancers17020282.","DOI":"10.3390\/cancers17020282"},{"key":"948_CR230","doi-asserted-by":"publisher","unstructured":"James TE, Alym A, Catherine M B, Agnes Yy L, Kevin A H, Ryan L H, et al. Weathering the COVID-19 storm: lessonsfrom hematologic cytokine syndromes. Blood Rev. 2020;45:100707. https:\/\/doi.org\/10.1016\/j.blre.2020.100707.","DOI":"10.1016\/j.blre.2020.100707"},{"key":"948_CR231","doi-asserted-by":"publisher","unstructured":"Arjun KG, Daniel HC, Avirup G, Strachan M, W JM, Claire R. CAR t cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? JACC CardioOncol. 2020;2(1):97\u2013109. https:\/\/doi.org\/10.1016\/j.jaccao.2020.02.011.","DOI":"10.1016\/j.jaccao.2020.02.011"},{"issue":"3","key":"948_CR232","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.7150\/thno.51383","volume":"11","author":"J Chen","year":"2021","unstructured":"Chen J, Ding Z, Li S, Liu S, Xiao C, Li Z, et al. Targeting transforming growth factor-\u03b2 signaling for enhanced cancer chemotherapy. Theranostics. 2021;11(3):1345\u201363. https:\/\/doi.org\/10.7150\/thno.51383.","journal-title":"Theranostics"},{"issue":"5","key":"948_CR233","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1242\/jcs.095299","volume":"125","author":"S Lamouille","year":"2012","unstructured":"Lamouille S, Connolly E, Smyth JW, Akhurst RJ, Derynck R. TGF-\u03b2-induced activation of mTOR complex 2 drives epithelial\u2013mesenchymal transition and cell invasion. J Cell Sci. 2012;125(5):1259\u201373. https:\/\/doi.org\/10.1242\/jcs.095299.","journal-title":"J Cell Sci"},{"issue":"1","key":"948_CR234","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13578-023-01083-7","volume":"13","author":"EM Poursani","year":"2023","unstructured":"Poursani EM, Mercatelli D, Raninga P, Bell JL, Saletta F, Kohane FV, et al. Copper chelation suppresses epithelial-mesenchymal transition by inhibition of canonical and non-canonical TGF-\u03b2 signaling pathways in cancer. Cell Biosci. 2023;13(1):132. https:\/\/doi.org\/10.1186\/s13578-023-01083-7.","journal-title":"Cell Biosci"},{"issue":"11","key":"948_CR235","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3390\/cells8111387","volume":"8","author":"E Oh","year":"2019","unstructured":"Oh E, Hong J, Yun C. Regulatory T cells induce metastasis by increasing tgf-\u03b2 and enhancing the epithelial\u2013mesenchymal transition. Cells. 2019;8(11):1387. https:\/\/doi.org\/10.3390\/cells8111387.","journal-title":"Cells"},{"issue":"2","key":"948_CR236","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/cells9020428","volume":"9","author":"J Dudas","year":"2020","unstructured":"Dudas J, Ladanyi A, Ingruber J, Steinbichler TB, Riechelmann H. Epithelial to mesenchymal transition: a mechanism that fuels cancer radio\/chemoresistance. Cells. 2020;9(2):428. https:\/\/doi.org\/10.3390\/cells9020428.","journal-title":"Cells"},{"issue":"11","key":"948_CR237","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1158\/0008-5472.CAN-20-3175","volume":"81","author":"Y Meng","year":"2021","unstructured":"Meng Y, Zhao Q, An L, Jiao S, Li R, Sang Y, et al. A TNFR2\u2013hnRNPK axis promotes primary liver cancer development via activation of YAP signaling in hepatic progenitor cells. Cancer Res. 2021;81(11):3036\u201350. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3175.","journal-title":"Cancer Res"},{"issue":"2","key":"948_CR238","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jaad.2020.12.010","volume":"8","author":"J Deng","year":"2018","unstructured":"Michael JM, Jeffrey MC, Matthew DV, William D. Paradoxical eruptions to targeted therapies in dermatology: a systematicreview and analysis. J Am Acad Dermatol. 2020;86(5):1080\u20131091. https:\/\/doi.org\/10.1016\/j.jaad.2020.12.010.","journal-title":"Cancer Discov"},{"key":"948_CR239","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2025.01.003","volume":"85","author":"WL Thuya","year":"2025","unstructured":"Thuya WL, Cao Y, Ho PC-L, Wong AL-A, Wang L, Zhou J, et al. Insights into IL-6\/JAK\/STAT3 signaling in the tumor microenvironment: implications for cancer therapy. Cytokine Growth Factor Rev. 2025;85:26\u201342. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.01.003.","journal-title":"Cytokine Growth Factor Rev"},{"key":"948_CR240","doi-asserted-by":"publisher","unstructured":"Neo SY, Tong L, Chong J, Liu Y, Jing X, Oliveira MMS, et al. Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6\/STAT3 axis. Sci Transl Med. 2024;16(747):eadi 2952. https:\/\/doi.org\/10.1126\/scitranslmed.adi2952.","DOI":"10.1126\/scitranslmed.adi2952"},{"issue":"2","key":"948_CR241","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/biology10020141","volume":"10","author":"DS Chulpanova","year":"2021","unstructured":"Chulpanova DS, Gilazieva ZE, Kletukhina SK, Aimaletdinov AM, Garanina EE, James V, et al. Cytochalasin B-Induced membrane vesicles from human mesenchymal stem cells overexpressing IL2 are able to stimulate CD8+ T-Killers to kill human triple negative breast cancer cells. Biol (Basel). 2021;10(2):141. https:\/\/doi.org\/10.3390\/biology10020141.","journal-title":"Biol (Basel)"},{"issue":"12","key":"948_CR242","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41556-022-01024-5","volume":"24","author":"J Bae","year":"2022","unstructured":"Bae J, Liu L, Moore C, Hsu E, Zhang A, Ren Z, et al. IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer. Nat Cell Biol. 2022;24(12):1754\u201365. https:\/\/doi.org\/10.1038\/s41556-022-01024-5.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"948_CR243","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","volume":"40","author":"Y Hailemichael","year":"2022","unstructured":"Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel S, Daher M, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40(5):509\u201323.e6. https:\/\/doi.org\/10.1016\/j.ccell.2022.04.004.","journal-title":"Cancer Cell"},{"key":"948_CR244","doi-asserted-by":"publisher","unstructured":"Bailey CM, Liu Y, Liu M, Du X, Devenport M, Zheng P, et al. Targeting HIF-1\u03b1 abrogates PD-L1\u2013mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. J Clin Investigation. 2022;132(9):e150846. https:\/\/doi.org\/10.1172\/JCI150846.","DOI":"10.1172\/JCI150846"},{"issue":"1","key":"948_CR245","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","volume":"12","author":"G Agliardi","year":"2021","unstructured":"Agliardi G, Liuzzi AR, Hotblack A, De Feo D, N\u00fa\u00f1ez N, Stowe CL, et al. Intratumoral IL-12 delivery empowers CAR-t cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021;12(1):444. https:\/\/doi.org\/10.1038\/s41467-020-20599-x.","journal-title":"Nat Commun"},{"key":"948_CR246","doi-asserted-by":"publisher","unstructured":"Mucciolo G, Curcio C, Roux C, Li WY, Capello M, Curto R, et al. IL17a critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Proc Natl Acad Sci USA. 2021;118(6):e2020395118. https:\/\/doi.org\/10.1073\/pnas.2020395118.","DOI":"10.1073\/pnas.2020395118"},{"key":"948_CR247","doi-asserted-by":"publisher","first-page":"120552","DOI":"10.1016\/j.biomaterials.2020.120552","volume":"268","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Muhetaerjiang M, An H, Fang X, Zhao Y, Wang H. Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy. Biomaterials. 2021;268:120552. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120552.","journal-title":"Biomaterials"},{"key":"948_CR248","doi-asserted-by":"publisher","first-page":"1592795","DOI":"10.3389\/fimmu.2025.1592795","volume":"16","author":"R Wang","year":"2025","unstructured":"Wang R, Kubiatowicz LJ, Zhang R, Bao L, Fang RH, Zhang L. Nanoparticle approaches for manipulating cytokine delivery and neutralization. Front. Immunol. 2025;16:1592795. https:\/\/doi.org\/10.3389\/fimmu.2025.1592795.","journal-title":"Front. Immunol"},{"issue":"1","key":"948_CR249","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ymthe.2024.11.027","volume":"33","author":"N Silva-Pilipich","year":"2025","unstructured":"Silva-Pilipich N, Beloki U, Apaolaza P, Igea A, Salaberry L, Prats-Mari L, et al. Targeting PD-1+ T cells with small-format immunocytokines enhances IL-12 antitumor activity. Mol Ther. 2025;33(1):297\u2013316. https:\/\/doi.org\/10.1016\/j.ymthe.2024.11.027.","journal-title":"Mol Ther"},{"key":"948_CR250","doi-asserted-by":"publisher","unstructured":"Daniela S, Harald W. TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond. Nat Rev Rheumatol. 2023;19(9):576\u201391. https:\/\/doi.org\/10.1038\/s41584-023-01002-7.","DOI":"10.1038\/s41584-023-01002-7"},{"key":"948_CR251","doi-asserted-by":"publisher","unstructured":"Natalia G. Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders. Front Immunol. 2023;19(9):576\u201391. https:\/\/doi.org\/10.3389\/fimmu.2023.1213448.","DOI":"10.3389\/fimmu.2023.1213448"},{"key":"948_CR252","doi-asserted-by":"publisher","unstructured":"Dan-In J, A-Hyeon L, Hye-Yoon S, Hyo-Ryeong S, Jong-Hwi P, Tae-Bong K, et al. The role of tumor necrosis factor alpha(TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):2719. https:\/\/doi.org\/10.3390\/ijms22052719.","DOI":"10.3390\/ijms22052719"},{"key":"948_CR253","doi-asserted-by":"publisher","unstructured":"Valentina A, Silvia D, Serena Z, Mathieu R, David K, Stefano U, et al. Tackling TNF-\u03b1 in autoinflammatory disordersandautoimmune diseases: from conventional to cutting edge in biologics and RNA- based nanomedicines. Adv Drug Deliv Rev. 2023;201:115080. https:\/\/doi.org\/10.1016\/j.addr.2023.115080.","DOI":"10.1016\/j.addr.2023.115080"},{"key":"948_CR254","doi-asserted-by":"publisher","unstructured":"Michael C, Shahram S, Carl F W. Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer. Nat Rev Drug Discov. 2024;23(12):939\u201361. https:\/\/doi.org\/10.1038\/s41573-024-01053-9.","DOI":"10.1038\/s41573-024-01053-9"},{"key":"948_CR255","doi-asserted-by":"publisher","unstructured":"Dario C, Jessica C. Therapeutic drugmonitoring of TNF\u03b1 inhibitors: a spotlight on novel techniques and assays. Expert Opin Drug Metab Toxicol. 2022;18(10):615\u201322. https:\/\/doi.org\/10.1080\/17425255.2022.2134775.","DOI":"10.1080\/17425255.2022.2134775"},{"key":"948_CR256","doi-asserted-by":"publisher","unstructured":"Jill LK, Troy AH, Jukyung K, Sang Yeop K, Preethi K, Michael F, et al. Physicochemical characterization andfunctionality comparison of humira\u00ae(adalimumab), remicade\u00ae(infliximab) and simponi aria\u00ae(golimumab). Int J Pharm. 2023;635:122646. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122646.","DOI":"10.1016\/j.ijpharm.2023.122646"},{"key":"948_CR257","doi-asserted-by":"publisher","unstructured":"Shuyi W, Rufei X, Yibo C, Yishan Y, Tianzhen H, Yang Y, et al. Anti-tumor necrosis factor therapy in the treatment of systemic autoinflammatory diseases: the responses of innate immune cells. J Leukoc Biol. 2025;117(5). https:\/\/doi.org\/10.1093\/jleuko\/qiaf026.","DOI":"10.1093\/jleuko\/qiaf026"},{"issue":"1","key":"948_CR258","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/immuno4010002","volume":"4","author":"LL Bastos","year":"2024","unstructured":"Bastos LL, Mariano D, Lemos RP, Bialves TS, Oliveira CJF, de Melo-Minardi RC. The role of structural bioinformatics in understanding tumor necrosis factor \u03b1-interacting protein mechanisms in chronic inflammatory diseases: a review. Immuno. 2024;4(1):14\u201342. https:\/\/doi.org\/10.3390\/immuno4010002.","journal-title":"Immuno"},{"key":"948_CR259","doi-asserted-by":"publisher","unstructured":"Richard OW, Felix Il C, H Y-S, Wen-YiT,Trevor W S. TNFR2 signalling in inflammatory diseases. Best Pract Res Clin Rheumatol. 2024;38(2):101941. https:\/\/doi.org\/10.1016\/j.berh.2024.101941.","DOI":"10.1016\/j.berh.2024.101941"},{"issue":"4","key":"948_CR260","doi-asserted-by":"publisher","first-page":"309","DOI":"10.33263\/BRIAC134.309","volume":"13","author":"RFH Msam","year":"2022","unstructured":"Msam RFH. Etanercept and infliximab, two tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors with different action profiles: an in vitro and in vivo study in the context of reviewed therapeutic applications. Biointerface Res Appl Chem 2022. 2022;13(4):309. https:\/\/doi.org\/10.33263\/BRIAC134.309.","journal-title":"Biointerface Res Appl Chem 2022"},{"key":"948_CR261","doi-asserted-by":"publisher","unstructured":"Ioana Ruxandra M, Alexandra Maria B, Ioana Irina R, M C, Luana Andreea M, Anca C, et al. Inflammatory bowel disease as a paradoxical reaction to anti-TNF-\u03b1 treatment-a review. Life (Basel). 2023;13(8):1779. https:\/\/doi.org\/10.3390\/life13081779.","DOI":"10.3390\/life13081779"},{"key":"948_CR262","doi-asserted-by":"publisher","unstructured":"Zhe Y, Ling G, Yinshan Z, Lu C, Wenjia G, Yan X. Adalimumab exhibits superiority over etanercept in terms of a numericallyhigher response rate and equivalent adverse events: a real-world finding. Immun Inflamm Dis. 2024;12(2):e1166. https:\/\/doi.org\/10.1002\/iid3.1166.","DOI":"10.1002\/iid3.1166"},{"key":"948_CR263","doi-asserted-by":"publisher","unstructured":"Cong D, Min J, Ming-Jun S. Letter: increased risk of developing crohn\u2019s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNF\u03b1 agents, particularly etanercept, for autoimmune diseases other than IBD. Aliment. Pharmacol. Ther. 2019;50(7):834\u201335. https:\/\/doi.org\/10.1111\/apt.15460.","DOI":"10.1111\/apt.15460"},{"key":"948_CR264","doi-asserted-by":"publisher","unstructured":"Sandy H, Sudharshan A, Rani B, Janice L, Cindy X W, John G, et al. Some drugs have two faces: paradoxical colitis inapatient with psoriatic arthritis previously treated with etanercept and IL-17 inhibitors. Dig Dis Sci. 2024;69(5):1602\u201307. https:\/\/doi.org\/10.1007\/s10620-024-08380-2.","DOI":"10.1007\/s10620-024-08380-2"},{"key":"948_CR265","doi-asserted-by":"publisher","unstructured":"Markus F N. Strategies for targetingcytokines in inflammatory bowel disease. Nat Rev Immunol. 2024;24(8):559\u201376. https:\/\/doi.org\/10.1038\/s41577-024-01008-6.","DOI":"10.1038\/s41577-024-01008-6"},{"key":"948_CR266","doi-asserted-by":"publisher","unstructured":"Yijie S, Man Y, Yu X, Hongxi X. Tackling inflammatory bowel diseases: targeting proinflammatory cytokines and lymphocyte homing. Pharmaceuticals (Basel). 2022;15(9):1080. https:\/\/doi.org\/10.3390\/ph15091080.","DOI":"10.3390\/ph15091080"},{"key":"948_CR267","doi-asserted-by":"publisher","unstructured":"Benoit LS. Insights into the biology andtherapeutic implications of TNF and regulatory t cells. Nat Rev Rheumatol. 2021;17(8):487\u2013504. https:\/\/doi.org\/10.1038\/s41584-021-00639-6.","DOI":"10.1038\/s41584-021-00639-6"},{"key":"948_CR268","doi-asserted-by":"publisher","unstructured":"Hiroshi N, Noriko S, Naomi M, YoshikoI.The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2021;21(3):103017. https:\/\/doi.org\/10.1016\/j.autrev.2021.103017.","DOI":"10.1016\/j.autrev.2021.103017"},{"key":"948_CR269","doi-asserted-by":"publisher","unstructured":"Adela M, Branka M, Zrinka B. New andemerging targeted therapies for hidradenitis suppurativa. Int J Mol Sci. 2022;23(7):3753. https:\/\/doi.org\/10.3390\/ijms23073753.","DOI":"10.3390\/ijms23073753"},{"key":"948_CR270","doi-asserted-by":"publisher","unstructured":"Tim S, Juliane L, Christoph G. IL-6 signaling in immunopathology: from basic biology to selective therapeutic intervention. ImmunoTargets Ther. 2025;Volume 14:681\u2013695. https:\/\/doi.org\/10.2147\/ITT.S485684.","DOI":"10.2147\/ITT.S485684"},{"key":"948_CR271","doi-asserted-by":"publisher","unstructured":"Annika G, Julia E, Julia W, Christoph W, Stephan P, Giacomo P, et al. Bispecific soluble cytokine receptor-nanobody fusions inhibit interleukin (IL-)6 trans-signaling and IL-12\/23 or tumor necrosis factor (TNF) signaling. J Biol Chem. 2023;299(11):105343. https:\/\/doi.org\/10.1016\/j.jbc.2023.105343.","DOI":"10.1016\/j.jbc.2023.105343"},{"key":"948_CR272","doi-asserted-by":"publisher","unstructured":"Mengchen A, Mengxiao S, Jingjing S, Yueru W, Rongrong L, Pengchao S, et al. Dual-drug loaded separable microneedles for efficient rheumatoid arthritis therapy. Pharmaceutics. 2022;14(7):1518. https:\/\/doi.org\/10.3390\/pharmaceutics14071518.","DOI":"10.3390\/pharmaceutics14071518"},{"key":"948_CR273","doi-asserted-by":"publisher","unstructured":"Tudorita Gabriela P, Ivona M, Mariana P, Manuel Florin R, Ionela-Larisa M, Daniela C, et al. Cytokine storm in COVID-19: exploring IL-6 signaling and cytokine-microbiome interactions as emerging therapeutic approaches. Int J Mol Sci. 2024;25(21):11411. https:\/\/doi.org\/10.3390\/ijms252111411.","DOI":"10.3390\/ijms252111411"},{"key":"948_CR274","doi-asserted-by":"publisher","unstructured":"Christine L, Jacqueline K, Roy F, Massimo G, John J O. A decade of JAK inhibitors: what have we learned and what may be the future? Arthritis Rheumatol 2021;73(12):2166\u201378. https:\/\/doi.org\/10.1002\/art.41906.","DOI":"10.1002\/art.41906"},{"issue":"1","key":"948_CR275","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s13046-022-02564-2","volume":"41","author":"L Liu","year":"2022","unstructured":"Liu L, Gao J, Xing X, Jiang M, Liu Q, Wang S, et al. Cyclin g2 in macrophages triggers CTL-mediated antitumor immunity and antiangiogenesis via interferon-gamma. J Exp Clin Cancer Res. 2022;41(1):358. https:\/\/doi.org\/10.1186\/s13046-022-02564-2.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"948_CR276","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","volume":"20","author":"DV Sawant","year":"2019","unstructured":"Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, et al. Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019;20(6):724\u201335. https:\/\/doi.org\/10.1038\/s41590-019-0346-9.","journal-title":"Nat Immunol"},{"issue":"18","key":"948_CR277","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1158\/0008-5472.CAN-23-3553","volume":"84","author":"D Schmidt","year":"2024","unstructured":"Schmidt D, Endres C, Hoefflin R, Andrieux G, Zwick M, Karantzelis N, et al. Oncogenic calreticulin induces immune escape by stimulating TGF\u03b2 expression and regulatory t-cell expansion in the bone marrow microenvironment. Cancer Res. 2024;84(18):2985\u20133003. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-3553.","journal-title":"Cancer Res"},{"issue":"1","key":"948_CR278","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","volume":"7","author":"EI Buchbinder","year":"2019","unstructured":"Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, et al. Therapy with high-dose interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J. Immunother Cancer. 2019;7(1):49. https:\/\/doi.org\/10.1186\/s40425-019-0522-3.","journal-title":"J. Immunother Cancer"},{"issue":"5","key":"948_CR279","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.urology.2014.02.005","volume":"83","author":"M Hanzly","year":"2014","unstructured":"Hanzly M, Aboumohamed A, Yarlagadda N, Creighton T, Digiorgio L, Fredrick A, et al. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. Urology. 2014;83(5):1129\u201334. https:\/\/doi.org\/10.1016\/j.urology.2014.02.005.","journal-title":"Urology"},{"issue":"12","key":"948_CR280","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","volume":"1","author":"I Solomon","year":"2020","unstructured":"Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, et al. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nat Cancer. 2020;1(12):1153\u201366. https:\/\/doi.org\/10.1038\/s43018-020-00133-0.","journal-title":"Nat Cancer"},{"issue":"1","key":"948_CR281","doi-asserted-by":"publisher","first-page":"1899671","DOI":"10.1080\/2162402X.2021.1899671","volume":"10","author":"J Kim","year":"2021","unstructured":"Kim J, Lee J, Park S, Lee YJ, Kim M. Crystal structure of human interleukin-2 in complex with TCB2, a new antibody-drug candidate with antitumor activity. Oncoimmunology. 2021;10(1):1899671. https:\/\/doi.org\/10.1080\/2162402X.2021.1899671.","journal-title":"Oncoimmunology"},{"issue":"1","key":"948_CR282","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41467-020-14471-1","volume":"11","author":"M Sharma","year":"2020","unstructured":"Sharma M, Khong H, Fa\u2019ak F, Bentebibel S, Janssen LME, Chesson BC, et al. Bempegaldesleukin selectively depletes intratumoral tregs and potentiates t cell-mediated cancer therapy. Nat Commun. 2020;11(1):661. https:\/\/doi.org\/10.1038\/s41467-020-14471-1.","journal-title":"Nat Commun"},{"issue":"6379","key":"948_CR283","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.aar3246","volume":"359","author":"JT Sockolosky","year":"2018","unstructured":"Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, et al. Selective targeting of engineered t cells using orthogonal IL-2 cytokine-receptor complexes. Sci (New Y, N.Y.). 2018;359(6379):1037\u201342. https:\/\/doi.org\/10.1126\/science.aar3246.","journal-title":"Sci (New Y, N.Y.)"},{"issue":"7738","key":"948_CR284","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","volume":"565","author":"D Silva","year":"2019","unstructured":"Silva D, Yu S, Ulge UY, Spangler JB, Jude KM, Lab\u00e3o-Almeida C, et al. De Novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019;565(7738):186\u201391. https:\/\/doi.org\/10.1038\/s41586-018-0830-7.","journal-title":"Nature"},{"issue":"12","key":"948_CR285","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1158\/1078-0432.CCR-20-4575","volume":"27","author":"JA Foltz","year":"2021","unstructured":"Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, et al. Phase i trial of n-803, an IL15 receptor agonist, with rituximab in patients with indolent non-hodgkin lymphoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2021;27(12):3339\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4575.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"12","key":"948_CR286","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3390\/cells12121611","volume":"12","author":"G Lui","year":"2023","unstructured":"Lui G, Minnar CM, Soon-Shiong P, Schlom J, Gameiro SR. Exploiting an interleukin-15 heterodimeric agonist (n803) for effective immunotherapy of solid malignancies. Cells. 2023;12(12):1611. https:\/\/doi.org\/10.3390\/cells12121611.","journal-title":"Cells"},{"key":"948_CR287","doi-asserted-by":"publisher","unstructured":"Kepp O, Zitvogel L, Kroemer G. Clinical evidence that immunogenic cell death sensitizes to PD-1\/PD-l1 blockade. Oncoimmunology. 2019;8(10):e1637188. https:\/\/doi.org\/10.1080\/2162402X.2019.1637188.","DOI":"10.1080\/2162402X.2019.1637188"},{"issue":"1","key":"948_CR288","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7150\/jca.21414","volume":"9","author":"C Jiang","year":"2018","unstructured":"Jiang C, Cai X, Zhang H, Xia X, Zhang B, Xia L. Activity and immune correlates of a programmed death-1 blockade antibody in the treatment of refractory solid tumors. J Cancer. 2018;9(1):205\u201312. https:\/\/doi.org\/10.7150\/jca.21414.","journal-title":"J Cancer"},{"issue":"8047","key":"948_CR289","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR t cells for patients with solid cancers. Nature. 2025;637(8047):940\u201346. https:\/\/doi.org\/10.1038\/s41586-024-08261-8.","journal-title":"Nature"},{"issue":"1","key":"948_CR290","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1756-9966-32-97","volume":"32","author":"P Kachroo","year":"2013","unstructured":"Kachroo P, Lee M, Zhang L, Baratelli F, Lee G, Srivastava MK, et al. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res. 2013;32(1):97. https:\/\/doi.org\/10.1186\/1756-9966-32-97.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"948_CR291","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41392-022-01147-z","volume":"7","author":"H Gong","year":"2022","unstructured":"Gong H, Ma S, Chen J, Yang B, Liu S, Liu X, et al. Dendritic cell-derived IL-27 p28 regulates t cell program in pathogenicity and alleviates acute graft-versus-host disease. Sig Transduct Target Ther. 2022;7(1):319. https:\/\/doi.org\/10.1038\/s41392-022-01147-z.","journal-title":"Sig Transduct Target Ther"},{"key":"948_CR292","doi-asserted-by":"publisher","unstructured":"Smith HG, Cartwright J, Wilkinson MJ, Strauss DC, Thomas JM, Hayes AJ. Isolated limb perfusion with melphalan and tumour necrosis factor \u03b1 for in-transit melanoma and soft tissue sarcoma. Ann Surg Oncol. 2015;22Suppl, S3):S356\u2013361. https:\/\/doi.org\/10.1245\/s10434-015-4856-x.","DOI":"10.1245\/s10434-015-4856-x"},{"issue":"10","key":"948_CR293","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1111\/cas.12504","volume":"105","author":"Q Du","year":"2014","unstructured":"Du Q, Jiang L, Wang X, Wang M, She F, Chen Y. Tumor necrosis factor-\u03b1 promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-\u03bab-mediated upregulation of vascular endothelial growth factor-c. Cancer Sci. 2014;105(10):1261\u201371. https:\/\/doi.org\/10.1111\/cas.12504.","journal-title":"Cancer Sci"},{"issue":"1","key":"948_CR294","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","volume":"14","author":"B Kim","year":"2021","unstructured":"Kim B, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ. Novel therapies emerging in oncology to target the TGF-\u03b2 pathway. J Hematol Oncol. 2021;14(1):55. https:\/\/doi.org\/10.1186\/s13045-021-01053-x.","journal-title":"J Hematol Oncol"},{"key":"948_CR295","doi-asserted-by":"publisher","unstructured":"Rajan A, Abdul Sater H, Rahma O, Agajanian R, Lassoued W, Mart\u00e9 JL, et al. Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-l1, in patients with advanced non-small cell lung cancer. J Immunother Cancer. 2024;12(3):e008480. https:\/\/doi.org\/10.1136\/jitc-2023-008480.","DOI":"10.1136\/jitc-2023-008480"},{"key":"948_CR296","doi-asserted-by":"publisher","unstructured":"Yoo C, Oh D, Choi HJ, Kudo M, Ueno M, Kondo S, et al. Phase i study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-l1, in patients with pretreated biliary tract cancer. J Immunother Cancer. 2020;8(1):e000564. https:\/\/doi.org\/10.1136\/jitc-2020-000564.","DOI":"10.1136\/jitc-2020-000564"},{"key":"948_CR297","doi-asserted-by":"publisher","unstructured":"Ludovico D, Francesca Bobbio P, Eleonora M, Veronica P, Enrico Maria V, Carlomaurizio M, et al. Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders. Autoimmun Rev. 2023;22(7):103332. https:\/\/doi.org\/10.1016\/j.autrev.2023.103332.","DOI":"10.1016\/j.autrev.2023.103332"},{"key":"948_CR298","doi-asserted-by":"publisher","unstructured":"Panagiotis T, Panagiotis T, Konstantinos T, Dimitris T. The impact of cytokines in coronary atherosclerotic plaque: current therapeutic approaches. Int J Mol Sci. 2022;23(24):15937. https:\/\/doi.org\/10.3390\/ijms232415937.","DOI":"10.3390\/ijms232415937"},{"key":"948_CR299","doi-asserted-by":"publisher","unstructured":"Kathryn MC, James N K. Long-term outcomes following CAR t cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1.","DOI":"10.1038\/s41571-023-00754-1"},{"key":"948_CR300","doi-asserted-by":"publisher","unstructured":"Jayapriya J, Michael P M, Andrew JH,Ruchi P D, Audrey W F, An HuynhThuy P, et al. CAR-t design: elements and their synergistic function. EBioMedicine. 2020;58:102931. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102931.","DOI":"10.1016\/j.ebiom.2020.102931"},{"key":"948_CR301","doi-asserted-by":"publisher","unstructured":"Victor E Th T, Chandra M. Biomarkers for predicting cytokine release syndrome following CD19-targeted CAR t cell therapy. J Immunol. 2021;206(7):1561\u201368. https:\/\/doi.org\/10.4049\/jimmunol.2001249.","DOI":"10.4049\/jimmunol.2001249"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00948-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00948-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00948-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:55:58Z","timestamp":1783018558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00948-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":301,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00948-6","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable. This manuscript does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Not applicable. This manuscript does not include details, images, or videos relating to an individual person.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}